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ABSTRACT 
 
A collection of Erysipelothrix rhusiopathiae swine, fish, and cetacean strains 
representing nearly all 16 serotypes was analyzed for possession of the surface protective 
antigen (spa) family of genes and their expression products.  Polymerase chain reaction 
(PCR) assays utilizing primers specific for spaA, spaB and spaC revealed that spa-type is 
not absolutely associated with serotype when two strains of serotypes previously reported 
to possess spaB produced amplicons with spaA-specific primers. These results were 
supported when a monoclonal antibody, specific for the protective domain of SpaA, 
reacted strongly in Western blotting with a 65 kilodalton (kDa) protein from both strains. 
Vaccination challenge studies were conducted in mice to evaluate an E. rhusiopathiae 
bacterin composed of a serotype 2 SpaA-type swine strain in its ability to protect mice 
against challenge with virulent fish and cetacean strains of various spa-types.  Vaccinated 
mice were completely protected against challenge strains possessing spaA but variably 
protected against challenge strains possessing heterologous spa or more than one spa-
type.
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CHAPTER 1.  GENERAL INTRODUCTION 
 
Introduction 
Erysipelas, a disease caused by the gram-positive bacterium Erysipelothrix 
rhusiopathiae, is distributed worldwide and has an economic and epidemiological impact 
on animal production and handling.  With several outbreaks of the disease being reported 
every year in various settings from swine finishing operations to marine aquaria, the 
disease is significant and control is vitally important.  Currently in the United States, 
killed E. rhusiopathiae vaccines (bacterins) are used to prevent clinical signs of the 
disease.   
The USDA-Center for Veterinary Biologics (CVB) implements the provisions of 
the Virus-Serum-Toxin Act to ensure that veterinary biologics used for the diagnosis, 
prevention, and treatment of animal diseases are pure, safe, potent, and effective.  There 
are several erysipelas bacterins licensed by the USDA for use in controlling swine 
erysipelas.  In order to receive licensure, biologics manufacturers must comply with 
regulations in Title 9 of the Code of Federal Regulations (9CFR).  
Part of the regulation of bacterins includes a demonstration of efficacy which 
requires the possession of a standardized reference bacterin proven efficacious in the host 
animal.  The validated reference bacterin is subsequently used as a control to measure 
relative potency of each erysipelas bacterin lot produced by the manufacturer.  Each lot 
must perform equal to or better than the reference bacterin to be released for sale.  A 
mouse potency test shown to correlate with the swine (host animal) test when mice and 
swine are challenge-exposed after vaccination is used for serial potency testing of 
erysipelas bacterins.    
The mouse potency assay is an in vivo vaccination-challenge assay that measures 
the dose required to protect 50% of vaccinated mice from a virulent challenge dose, 
administered two to three weeks after vaccination.  It compares the dose required to 
protect 50% (PD50) of vaccinated mice to the PD50 of a reference bacterin which has 
proven efficacy in swine.  A satisfactory potency test requires that the PD50 ratio of the 
serial to the reference be equal or greater than 0.6.   
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In the early 1990’s, the CVB established an in vitro parallel line assay [1] as an 
alternative to the mouse test for determining relative potency of erysipelas bacterins for 
serial release.  The enzyme-linked immunosorbent assay (ELISA) utilizes a monoclonal 
antibody developed through studies at the CVB [2] to specifically recognize the putative 
64-66 kilodalton (kDa) protective membrane protein of E. rhusiopathiae.  The CVB 
supplies the monoclonal antibody, named ERHU-B60-91, to biologics manufacturers for 
use in the ELISA which may now replace the mouse test for determining the relative 
potency of individual serials to a validated reference bacterin.   
Since development and implementation of the ELISA potency test, much more is 
known about the 64-66 kDa membrane proteins of E. rhusiopathiae.  The family of 
proteins has been named surface protective antigen (Spa) and includes three types, SpaA, 
SpaB, and SpaC.  The amino acid sequences of each type have been elucidated and the 
molecular domain structure has been described [3].  Based on sequence analysis of Spas 
from several Erysipelothrix serotype reference strains, it has been reported that SpaA is 
produced in serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N; SpaB is produced in 
serotypes 4, 6, 11, 19 and 21; and SpaC is produced in the Erysipelothrix serotype 18 [3].    
With the use of ERHU-B60-91 in the ELISA, the CVB depends heavily on the 
detection of a single protective antigen in determining the potency of erysipelas bacterins, 
even though the molecular specificity of the monoclonal antibody is uncertain.  The first 
objective of this study was to fully investigate the specificity of ERHU-B60-91 by 
verifying the identity of the recognized 65 kDa protein as a Spa. 
Nearly all spa studies have been conducted on well characterized E. rhusiopathiae 
serotype reference strains [3, 4, 5, 6, 7, 8] and it is not yet certain that spa-type is 
confined to particular serotypes as reported by To and Nagai [3].  The second objective of 
this study was to survey an extensive E. rhusiopathiae collection of swine, fish and 
cetacean strains to determine whether spa-type is associated with serotype.   
Despite the importance of preventing erysipelas in marine mammals, there is no 
bacterin designed specifically for these animals.  Marine aquaria that do vaccinate 
cetaceans use bacterins “off-label” to prevent erysipelas outbreak in animals confined in 
these facilities.  Because little is known about the E. rhusiopathiae strains infecting 
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cetaceans, the swine bacterins used may not include strains that possess the protective 
antigens needed to elicit adequate protection in these animals.  The third objective of this 
study was to determine whether mice vaccinated with an established erysipelas reference 
bacterin, designed from a serotype 2 SpaA-type swine strain, can protect mice against 
challenge with virulent E. rhusiopathiae cetacean and fish strains of various serotypes 
and spa-types.   
 
Thesis Organization 
The manuscripts included in this thesis have been prepared for submission to 
scholarly journals and proceedings and follow the Iowa State University Graduate 
College thesis formatting requirements.  Thesis organization for a “Thesis Containing 
Journal Papers” is organized into a complete and comprehensive unit.  This document 
begins with a General Introduction stating the research problem and study objectives, 
followed by a complete literature review of the topic, and references.  Each of the 
following Chapters are organized as individual scholarly journal publications which 
include an abstract, introduction, materials and methods, results, discussion, 
acknowledgements, and references.  The last chapter of the thesis is the General 
Conclusion where the results of the study are discussed as they apply to the research 
problem and objectives outlined in the general introduction.  Additional information such 
as raw data, figures, and tables are contained in the Appendices.  Lastly, a full list of 
Acknowledgements completes the thesis document. 
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Literature Review 
Erysipelothrix is a small, mesophilic, facultatively anaerobic, nonsporeforming, 
gram-positive rod.  The organism is distributed worldwide and causes disease in many 
land and aquatic animals.  Erysipelothrix is considered a common commensal of the oral, 
pharyngeal, and intestinal mucosa of animals [9, 10] and has also been isolated from 
slime on the bodies of fish [11].  It has been well documented that seemingly healthy 
animals are carriers of the bacterium [10], with isolation most common from the lymph 
nodes and tonsils [9].  These organisms are ubiquitous in the environment especially 
where rodents and wild birds are frequently found.  The bacterium is quite resistant to 
normal environmental conditions and has been isolated from soil and water up to five 
months after being contaminated with animal feces [12].  Well-established principles of 
disease control are effective in controlling the organism in animal handling facilities and 
several common disinfectants are efficacious against the organism [10]. 
The genus Erysipelothrix was once thought to contain a single species,                
E. rhusiopathiae, made up of 24 serotypes based on peptidoglycan antigens of the cell 
wall [10].  Genetic analysis using DNA-DNA hybridization revealed distinct differences 
among E. rhusiopathiae strains, and subsequently the genus was divided into two distinct 
species, E. rhusiopathiae which include the serotypes 1a, 1b, 2, 4, 5, 6, 8, 9, 11, 12, 15, 
16, 17, 19, 21, and N, and E. tonsillarum containing serotypes 3, 7, 10, 14, 20, 22, and 
23, with serotypes 13 and 18 falling outside the two groups [9, 13, 14].   
With the acceptance of molecular technology for examining bacterial intraspecies 
genetic variations, the value of serotype identification of Erysipelothrix strains has been 
questioned for epidemiological study and taxonomic placement [11, 15, 16, 17].  
Recently a partial 16S rRNA gene sequence differing from either specie has been 
discovered which has led to the proposal of a third genus, E. inopinata [18] which may 
include strains from the unclassified serotypes 13, 18, as well as atypical serotype 7, 9, 
and 10 strains [11].  However, as of yet very few strains have been examined and more 
work needs to be done to support the addition of this novel specie.   
Erysipelothrix rhusiopathiae is most often associated with causing erysipelas in 
swine and turkeys [10, 19] but is also known to cause disease in cetaceans [20, 21] and 
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humans.  In humans, E. rhusiopathiae causes erysipeloid, and it is considered an 
occupational disease of those involved in handling animals and contaminated animal 
products [10, 19, 22].   Present data suggest that E. tonsillarum is avirulent in swine [11, 
23, 24] and perhaps most animal species except dogs, where several serotype 7 strains 
have been isolated from cases of endocarditis [11].   
Erysipelothrix rhusiopathiae is shed in feces, urine, saliva, and nasal secretions 
which typically gain entry into the body through skin abrasions or ingestion [10]. Stresses 
from the production environment including weaning, mixing groups of new animals, 
changes in feedstuffs and/or housing, or viral infections can increase the likelihood of 
erysipelas outbreaks in non-protected swine herds [5, 17].  It is suspected that cetaceans 
become exposed to the organism upon ingestion of fish contaminated with                      
E. rhusiopathiae [22, 25].  Infection usually manifests itself within a few days of 
exposure with the development of characteristic diamond-shaped urticarial skin lesions 
[10]; thus the resulting disease’s more common moniker “diamond-skin disease”.  
Erysipelas presents in three forms: acute septicemia, subacute, and chronic infection.   
Acute septicemia in swine is characterized by the sudden appearance of the 
classic urticarial diamond-shaped lesions, usually turning from a small light pink rash to 
an angry purple raised area on a light-skinned pig.  Palpation of the affected area on a 
dark-skinned pig reveals a firm raised welt [10]. Often if untreated, the lesions will blister 
and become necrotic.  In addition to skin lesions, obvious lameness is exhibited along 
with very high fever, depression, anorexia, and without antibiotic treatment, death can 
rapidly occur [10, 19, 26].  In marine mammals, acute septicemic infection can result in 
death even before clinical signs appear, making this a particularly feared disease in 
marine aquaria [27].   
Subacute erysipelas includes symptoms less severe than those presented in an 
acute case of the disease.  In swine, a few skin lesions may develop but do not become as 
inflamed, and a low-grade fever may occur but go undetected [10].  Subacute erysipelas 
in cetaceans is usually exhibited as diamond-shaped lesions on the anterior dorsal area of 
the skin [26].  Sloughing of the skin and development of abscesses may occur [21].  
Recovery from the disease can be achieved if penicillin-G is administered in a timely 
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manner to an animal showing acute or subacute signs of erysipelas.  Improvement is 
often evident within 24 hours of treatment [10].  
Chronic erysipelas usually follows an acute or subacute infection where self-
sustaining destructive pathological changes can occur in the heart valves and joints 
producing endocarditis and arthritis, respectively [10, 28, 29].  Arthritis caused by 
chronic erysipelas is considered an economic problem in the swine industry. Treatment is 
not effective and it is often more cost efficient for large operations to cull chronically 
affected individuals because of reduced growth rate.  At slaughter, chronically infected 
animals have significantly lower value due to carcass contamination with live bacteria.  A 
study by Hariharan et al. [30] found 37% of arthritic joints of slaughter hogs in Canada 
positive for bacterial growth.  Of the 67 bacterial isolates obtained from these joints, 45% 
were E. rhusiopathiae.   
The development of erysipelas-induced arthritis is considered to be dependent on 
cell-mediated immune responses [28, 29, 31, 32], and because of the physiological 
similarities, chronically affected animals have been regarded as valuable models for 
studying human rheumatoid arthritis [28, 29].  A study by Renz et al. [29] utilized rats to 
demonstrate the sequence of events that characterize the acute phase of E. rhusiopathiae-
induced arthritis.  It was shown that the inflammatory response leading to the 
development of arthritis was strongly dependent on the organism’s interaction with 
macrophages and T lymphocytes to enhance inflammatory mediator release.  The study 
suggested that persistent macrophage activation caused by continuously stimulated 
lymphocytes in certain locations such as joints was maintained in chronically infected 
animals for their lifetime.  The underlying cause of the presumed continuous lymphocyte 
stimulation was not revealed from the study.  
An investigation later published in 1995 by Franz et al. [28] continued those 
thoughts by reporting that E. rhusiopathiae organisms remained viable up to five months 
post-infection when the organism was reisolated from swine arthritic joints.  Viable           
E. rhusiopathiae was recovered from synovial fluid, synovial tissue, and from lysed 
chondrocytes of chronically infected pigs.  The study suggested that sequestration of 
viable bacteria in joint tissues is responsible for the chronic and self-sustaining nature of 
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erysipelas-induced arthritis, and that chondrocytes may function as antigen-presenting 
cells or provide a source of antigen to professional antigen-presenting cells.   
Prevention of erysipelas can be achieved by regular vaccination using killed 
bacterins or live attenuated vaccines [10, 17].  Commercial bacterins are usually prepared 
from a serotype 2 isolate [10] and induce cross-protection toward serotypes 1a, 1b, and 2 
(including subtypes 2a and 2b) which cause the majority of clinical disease in swine [24, 
33].  Formalin-killed aluminum hydroxide-adsorbed bacterins administered by 
intramuscular or subcutaneous injection and live attenuated vaccines administered orally 
confer an immunity that, in most cases, can protect growing pigs from acute disease until 
they reach market weight [10].   
Despite the importance of preventing erysipelas in cetaceans, bacterins formulated 
specifically for marine mammals are non-existent [27].  Marine facilities that do 
vaccinate for erysipelas use commercially available swine bacterins in marine 
immunization programs.  Because of cetaceans’ extreme sensitivity to the organism, live 
attenuated E. rhusiopathiae vaccines are not used in order to avoid the risk of the 
attenuated organism retaining virulence for cetaceans [20]. 
Erysipelothrix rhusiopathiae is a facultative intracellular pathogen which has 
been shown to survive well within murine macrophages [32] and polymorphonuclear 
leukocytes [34]; and it is believed that protection is dependent on both cell-mediated and 
humoral immune responses [5, 31, 35].  Protection elicited against the organism is not 
serotype specific as varying degrees of cross-protection among serotypes have been 
observed [23, 24, 36].  Passive protection can be produced by treating with antiserum 
against cross-protecting E. rhusiopathiae serotypes [10].  However, not all antibodies 
elicited towards a whole-cell E. rhusiopathiae antigen correlate with protection [37] as 
some are made towards non-protective, serotype-specific polysaccharide antigens [5].  
The fact that antibodies have shown protection against several serotypes suggests that the 
protective antigen(s) is conserved within the E. rhusiopathiae species [4, 5, 23, 33]. 
The hypothesis that protection against erysipelas depends on species-specific cell-
surface antigens has led to several investigations of the E. rhusiopathiae antigenic profile, 
and approaches to characterize those responsible for protection have been published [4, 5, 
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6, 7, 38, 39, 40, 41].  White and Verwey [40] used sequential ultracentrifugation to 
investigate soluble antigen acquired from concentrated E. rhusiopathiae culture 
supernatant fluids.  The sediment and supernatant acquired through each centrifugation 
step was tested for protective activity in mice.  The most protective activity was 
sedimented at low speeds, less than 20,000 x g, indicating that the protective antigen was 
of large size, estimated to be greater than 200,000 molecular weight.  However, 
protective activity was also found in supernatant and partially sedimented material 
through each centrifugation step, signifying that the protective antigen(s) may exist in a 
variety of molecular sizes, possibly resulting from degradation.  
In addition, enzymatic studies with lipase, ribonuclease, trypsin, and muramidase 
were performed on each fraction acquired through centrifugation.  Treatment with lipase 
and ribonuclease had no effect on the protective activity, whereas fractions treated with 
trypsin lost all activity.  Treatment with muramidase reduced protective activity of the 
fractions by 75%, indicating the presence of 1, 4 beta-glucosidic linkages of glycosamino 
peptides.  From this study it was postulated that the protective antigen of E. rhusiopathiae 
originates from the cell membrane. 
Continuing with their studies, White and Verwey [41] experimented with 
solubilizing the protective antigen from the 20,000 x g sediment with different detergents.  
According to turbidity measurements, sodium dodecyl sulfate (SDS) was the most 
effective in solubilizing the antigen.  Heterologous challenge experiments showed that 
SDS-solubilized extract from a serotype 1a isolate (strain HC-585) could protect against a 
virulent serotype 2 isolate (strain S-192), demonstrating that the solubilized protective 
antigen was a constituent of both serotypes.  In addition, fractionation analysis showed 
that the SDS-solubilized antigen was composed of major amounts of protein, lipid and 
some carbohydrate, suggesting the protective antigen was a glycolipoprotein.   
Later, Lachmann and Deicher [38] used SDS-polyacrylamide gel electrophoresis 
(PAGE) to separate detergent-solubilized E. rhusiopathiae cell-surface antigens of strain 
T-28 (serotype 2b).  Profiles of solubilized antigens prepared with various detergents 
revealed approximately 20 bands.  Two of these, a 64,000 and a 48,000 molecular weight 
band, were consistently prominent between treatments.  Immunoblotting with immune 
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rabbit serum revealed an identical pattern of antigens with the detection of two additional 
bands at 14,000 and 22,000 molecular weight.  These two bands did not correspond to 
any protein in the SDS-PAGE profile and upon enzymatic treatment, were assumed to be 
capsular polysaccharides.  The study ultimately showed that immune rabbit serum 
recognizes several different antigens of the E. rhusiopathiae cell membrane, with the 48 
and 64 kilodalton (kDa) proteins demonstrating significant reactivity; however, 
protection studies were not conducted with these proteins. 
In an effort to characterize the protein(s) believed to be the protective antigen of 
the species, Groshup et al. [5] examined two strains of E. rhusiopathiae, T28 (serotype 
2b) and Frankfurt XI (serotype N).  They showed that crude extracts of T28 generated 
from EDTA, EDTA-10 mM NaOH, and 10 mM NaOH could elicit significant levels of 
protection in mice against challenge with Frankfurt XI.  Extracts from both strains were 
analyzed by SDS-PAGE and immunoblot and showed that hyperimmune mouse, swine, 
and horse serum, as well as sera of convalescent pigs consistently recognized a prominent 
band of 64-66 kDa and another band at 39-40 kDa.  Both antigens had a tendency to 
aggregate unless solubilized in SDS and were found to be sensitive to treatment with 
trypsin with no detectable polysaccharide.  It was estimated that the protein in the study 
was perhaps a detergent solubilized constituent of the glycolipoprotein complex 
previously described [41]. 
The prominent protein was further characterized when a group of 40 mice were 
immunized with preparations of the 64-66 kDa band from a protein blot of strain T28.  
Upon challenge with virulent strain E1-6P (serotype 1a), all survived.  The pre-challenge 
sera of the mice reacted strongly with 64-66 kDa antigen in NaOH cell extracts, 
confirming previous suspicions that the protection stimulated was based on cell 
membrane proteins that are not serotype specific [23, 36].   
Galán and Timoney [4] later identified the 64-66 kDa protein as the protective 
antigen of E. rhusiopathiae by constructing a genomic library of the virulent strain      
E1-6P.  Total cell DNA was partially digested with EcoRI and packaged into lambda 
phage which recombined with Escherichia coli.  Clones that harbored antigens 
recognized by E. rhusiopathiae E1-6P convalescent pig serum were positively selected.  
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Two clones were further analyzed by their ability to protect mice against challenge.  Mice 
immunized with protein from recombinant E. coli lysates were poorly protected, 
however, when challenged with one hundred 50% lethal doses (LD50) of strain E1-6P, 
likely because the cloned protein was fused with β-galactosidase which interferes with 
the immune response [42]. 
To determine the size of the proteins being expressed by the two clones, guinea 
pigs were immunized with the lysate of a recombinant clone, and the antiserum was 
tested against detergent solubilized surface antigens and whole-cell extracts of various 
serotypes of E. rhusiopathiae.  Immunoblotting showed that the guinea pig antiserum 
consistently recognized polypeptides with molecular weights of 43, 64 and 66 kDa in all 
strains tested; the same molecular weight as prominent proteins mentioned in earlier 
studies [5, 38].  DNA analysis using Southern hybridization revealed that the DNA probe 
constructed from one of the clones shared homology with nine E. rhusiopathiae strains of 
various serotypes.  The fragment hybridized with a 5.4 kilobase (kb) EcoRI fragment in 
all strains except three with which it hybridized a slightly larger fragment; however, 
DNA sequences were not described in the study and the number of genes contained in the 
positive clones was not known. 
The first definitive characterization of the protective 64-66 kDa protein of           
E. rhusiopathiae was made by Makino et al. [7] in 1998.  This advancement was made by 
using a monoclonal antibody specific for the 64-66 kDa protein to select a single clone 
harboring the gene from a Sau3AI-digested Tama 96 (serotype 2) total DNA library 
expressed in E. coli.  The gene encoding this protein was given the name ‘surface 
protective antigen A’ (spaA) after mouse immunization experiments demonstrated that 
the gene expressed by E. coli could completely protect mice against E. rhusiopathiae 
Tama 96 challenge.  Deletion mutants were created from the cloned insert to determine 
the DNA sequence of the spaA gene.  Sequence data determined that the open reading 
frame (ORF) consisted of 1821 base pairs (bp) in the cloned region, corresponding to a 
66 kDa protein, approximately the same size as the protein recognized by the monoclonal 
antibody in Western blot analysis. 
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Makino et al. further examined the presence of spaA among the Erysipelothrix 
species using a 0.7 kb EcoRI fragment within the gene as a DNA probe in Southern 
hybridization analysis of EcoRI-digested DNA from strains representing                         
E. rhusiopathiae, E. tonsillarum, and Erysipelothrix serotypes 13 and 18.  Hybridization 
results showed that a gene homologous to the spaA probe was present in each                 
E. rhusiopathiae strain representing serotypes 1-2, 5, 8, 9, 12, 15-17 and N.  Hybridized 
fragments ranging in size from 0.7 to 23 kb indicated that restriction fragment 
polymorphism existed among the different strains.  A homologous gene could not be 
detected in strains representing E. rhusiopathiae serotypes 4, 6, 11, 19 and 21,                 
E. tonsillarum strains, or Erysipelothrix serotypes 13 and 18.  Results from this DNA 
analysis correlated well with Western blotting analysis and enzyme-linked 
immunosorbent assays (ELISA) performed on lysates of the same isolates using the 
SpaA-specific monoclonal antibody to detect the protein. 
Further analysis of the presumed amino acid sequence of SpaA found a 160 
amino acid region of the C-terminus organized into eight repeating units.  These 
repeating units were either identical or had very similar arrangements of 20 amino acids, 
always starting with glycine (G) or tryptophan (W) (Figure 1.1).   Homology searches 
found that the amino acid sequence of these repeating units to be highly homologous to 
the C-terminal regions of other cell-surface binding proteins of gram-positive bacteria, 
such as PspA, SpsA, and CbpA of Streptococcus pneumoniae.  These data were 
consistent with the belief that surface proteins containing GW modules at the C-terminus 
are involved in cell wall-binding behavior and, in the case of pneumococcal vaccines, 
may be important in eliciting protective antibody response [43].  Makino et al. concluded 
that the whole SpaA molecule, particularly the C-terminal repeat region, was essential for 
the protection observed in mice, despite the fact that specific protection experiments 
using purified SpaA were not conducted.  
An investigation by Imada et al. [6] later identified a 1,026 bp segment of spaA to 
contain the protective portion of the protein.  Exonuclease deletion mutants of plasmids 
containing full-length spaA from strain Fujisawa (serotype 1a) were expressed in E. coli 
and used to immunize mice.  An expressed fragment 342 amino acids in length, located at 
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the N-terminal end of the protein, was found to protect mice against challenge with the 
Japanese challenge strain Fujisawa.  The recombinant protein was composed of amino 
acids 89 through 431 fused to an N-terminal histidine hexamer tag, and was also found to 
protect pigs against lethal challenge with both Fujisawa and the serotype 2b strain, 82-
875 (Figure 1.2).  When analyzed by SDS-PAGE, the purified histidine-tagged 
recombinant SpaA (His-SpaA) showed the predicted size of 45.5 kDa and reacted well in 
an immunoblot with antiserum from E. rhusiopathiae-immunized mice and swine.  Sera 
from mice and swine immunized with His-SpaA were able to identify the 69 kDa intact 
native SpaA in an alkaline extract of strain Fujisawa. 
Additional analysis was performed on the His-SpaA immunized swine serum in in 
vitro phagocytosis studies.  Phagocytosis activity of immunized swine neutrophils was 
30% greater compared to those from non-immunized specific pathogen-free (SPF) swine 
serum with activity being attributed to enhanced opsonization of Fujisawa cells with 
antibodies to His-SpaA.  Upon opsonization of the cells, the number of live bacteria in 
neutrophils decreased significantly, nearly one logarithm difference.  Conversely, the 
viable bacterial count in monocytes was not affected by opsonization of antibody.  From 
these results, the major mechanism of protection was found to be enhanced phagocytic 
activity of neutrophils due to effective opsonization with anti-His-SpaA antibody.   
To further investigate spaA, the authors used polymerase chain reaction (PCR) to 
amplify the ORF from four strains of E. rhusiopathiae representing three serotypes 
important in swine.  DNA sequences of the protective region, approximately base pairs 
266 through 1294, were nearly identical.  Polymerase chain reaction-restriction fragment-
length polymorphism (PCR-RFLP) was performed on the PCR amplified gene from an 
additional 12 strains representing several E. rhusiopathiae serotypes.  Products of all 
except two strains showed the same restriction fragment pattern as Fujisawa with the five 
restriction enzymes used.  Products from the divergent strains gave different sized C-
terminal fragments, suggesting a variation in the number of C-terminal repeats in those 
strains. 
The region of SpaA responsible for protection was further studied by Shimoji et 
al. [8].  Whole spaA and the C-terminal repeat region were cloned, expressed in E. coli, 
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and purified to conduct immunization experiments in mice.  Mice actively immunized 
with the whole SpaA protein survived challenge with 10 LD50 of strain Fujisawa, whereas 
the mice immunized with purified C-terminal region of SpaA died within four days of 
challenge.  This result suggested that the C-terminal end does not play a major role in 
protection and was further confirmed by passive immunization experiments in mice.   
Anti-whole SpaA rabbit serum was absorbed with the purified recombinant C-
terminal repeat region of SpaA to obtain C-terminal specific antibodies.  Mice were 
treated with either the absorbed antiserum or the C-terminal specific antibodies, and then 
challenged with 10 LD50 of strain Fujisawa.  Of mice treated with the absorbed 
antiserum, 80% were protected while none of the mice treated with C-terminal specific 
antibodies survived challenge.  This investigation emphasized that the protective 
epitope(s) of SpaA is located within the N-terminal two-thirds of the protein and is 
important in eliciting humoral immunity. 
SpaA is also considered to be an important protective antigen in cetaceans and has 
been employed in measuring protective serum antibody titers of Atlantic bottlenose 
dolphins [21, 44, 45].  Osgood [45] cloned and expressed whole spaA from a cetacean 
isolate and compared its use in an indirect ELISA to native SpaA extracted from the same 
E. rhusiopathiae strain.  The antigens were each used to coat a microtiter plate to 
measure the serum antibody level from a known positive Atlantic bottlenose dolphin.  
Results from the experiments showed higher reactivity using the native SpaA than the 
recombinant whole protein.  The author suggested the differences may be attributed to 
abnormal protein folding arising in the purification process of the recombinant protein. 
Further investigation of SpaA for use in ELISA was conducted by Imada et al. 
[46].  Studying the protective region of SpaA, the group produced five separate 
recombinant truncated portions of the protein to compare in in vitro serological testing.  
Sizes of these proteins varied from 89 amino acids up to nearly full-length SpaA of 594 
amino acids and were used in an indirect ELISA to determine their sensitivity and 
specificity in detecting SpaA-specific swine antibodies.  The recombinant truncated 
proteins were used as the coating antigen and serum antibody titers were measured in the 
ELISA in terms of sample-positive (s/p) ratios (sample OD – negative OD)/(positive OD 
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– negative OD) using known negative and known positive sera as the controls for each 
test. 
   One recombinant protein, 416 amino acids in length (SpaA416), was selected as 
the ELISA antigen as it had the best yield and highest sensitivity in measuring SpaA-
specific antibodies.  The authors tested many different pigs at various stages of 
immunization to confirm the sensitivity and specificity of the SpaA416 ELISA, and 
found that the ELISA titers of the pre-challenge sera correlated well with the results of 
the challenge.   
Recently, To and Nagai [3] reported finding genetic and antigenic diversity within 
the spa gene of several E. rhusiopathiae strains.  Sequence analysis and antigenic studies 
contributed to expanding the repertoire of E. rhusiopathiae Spa proteins to include two 
additional types, SpaB and SpaC.  The authors designed primers which amplified genes 
encoding Spa proteins from 16 serotype reference strains of E. rhusiopathiae and a 
serotype 18 strain.  Sequence analysis of the amplified genes revealed ORFs ranging 
from 1,818 to 1,992 nucleotides in length, corresponding to proteins varying from 606-
664 amino acids.  Polymerase chain reaction experiments in E. tonsillarum strains and an 
Erysipelothrix serotype 13 strain yielded no DNA amplification, supporting a previous 
theory [7] that these species do not harbor the gene, and that the Spa proteins may be 
involved in the pathogenesis of E. rhusiopathiae.   
Based on the deduced amino acid sequences of Spas from Erysipelothrix serotype 
reference strains, To and Nagai divided the 17 Spa-positive serotypes into three groups 
depending on the Spa-type detected; SpaA was identified in serotypes 1a, 1b, 2, 5, 8, 9, 
12, 15, 16, 17, and N; SpaB was found in serotypes 4, 6, 11, 19, and 21; and SpaC from 
Erysipelothrix serotype 18.  Amino acid sequence comparison within Spa groups showed 
96-99% homology, but similarities among Spa groups were more variable with homology 
ranging from 61-67%.   
The authors further analyzed amino acid sequences of the three Spa groups and 
identified four distinct domains (Figure 1.3).  The N-terminal signal sequence was 
perfectly conserved, 100% homology, among all Spa groups and consisted of 29 amino 
acids.  The protective domain of the protein, beginning directly after the signal sequence, 
 15 
was found to be hypervariable in both length and sequence among Spa groups, with 
amino acid sequence homology in this domain ranging between 50-57%.   The amino 
acid sequences of the proline-rich hydrophobic domain, the section of the protein which 
joins the protective domain to the C-terminal 20-amino acid repeat region, was found to 
be especially variable among the Spa groups with homology ranging from 44-88%.  
Finally, the 20 amino acid C-terminal repeat sequence was consistent among groups, but 
the number of tandem repeats depended on type.  Both SpaA and SpaB groups contained 
nine tandem repeats while the SpaC-type had ten repeats.  One exception was the 
serotype 9 SpaA strain which had only eight tandem repeats. 
Spa proteins were further analyzed when ORFs from single strains representative 
of each spa group were successfully cloned and expressed in E. coli.  Purified 
recombinant SpaA, -B, and –C, emulsified with Freund’s complete adjuvant, was used to 
hyperimmunize rabbits to produce specific antiserum.  Immunoblotting analysis showed 
that each anti-Spa serum could detect an approximately 70 kDa protein in whole cell 
lysates prepared from homologous Spa strains, but were weakly reactive with 
heterologous strains; the most cross-reactivity observed was by anti-SpaC serum against 
SpaA strains. 
Cross-protection studies were also conducted by immunizing mice with the 
different recombinant Spas (rSpa).  Mice were immunized twice with a specific rSpa then 
separated into groups and challenged with an E. rhusiopathiae strain representing each 
Spa-type (Table 1.1).  Of the mice immunized with rSpaA, 100% survived challenge with 
Fujisawa, a serotype 1a SpaA strain; 50% survived challenge with Dolphin E-1, a 
serotype 6 SpaB strain; and 70% survived challenge with 715, a serotype 18 SpaC strain.   
Of the mice immunized with rSpaB, 100% survived homologous challenge, 40% 
survived challenge with the SpaA-type, and 60% survived challenge with the SpaC-type.  
The mice immunized with rSpaC were 100% protected by homologous challenge and 
90% of immunized mice survived challenge with both heterologous types.  These results 
showed that all rSpas have potent protective ability against homologous challenge but 
their ability to cross-protect is variable.  
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Figure 1.1 The SpaA protein of Tama-96 shown with 8 repeating units of 20 amino acids 
at the C-terminus. 
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Figure 1.2 Map of the cloned and expressed portion of the SpaA protective domain with 
a hexamer histidine tag at the N-terminus relative to the whole SpaA protein from strain 
Fujisawa. 
                           89                                                                  431 
 
  N                                                  C 
 
          6xHis 
 
 
 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 A general map of the Spa protein depicting location and relative size of each 
domain. 
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100% survived 60% survived 70% survived SpaC-type 
challenge 
90% survived 100% survived 50% survived SpaB-type 
challenge 
90% survived 40% survived 100% 
survived 
SpaA-type 
challenge 
Immunized w/ 
rSpaC 
Immunized w/ 
rSpaB 
Immunized 
w/ rSpaA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Rate of survival of mice immunized with different recombinant Spa groups and 
challenge with E. rhusiopathiae isolates representing homologous and heterologous Spa-
types. 
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CHAPTER 2.  THE MOLECULAR CHARACTERIZATION OF AN 
ERYSIPELOTHRIX RHUSIOPATHIAE-SPECIFIC MONOCLONAL ANTIBODY 
 
An unsubmitted paper  
 
Alaina L. Ingebritson 
 
Abstract 
Erysipelas is a bacterial disease with great economic impact to the swine industry.  
Clinical signs of the disease can be prevented through vaccination with killed 
Erysipelothrix rhusiopathiae bacterins.  The USDA-Center for Veterinary Biologics is 
responsible for implementing the Virus-Serum-Toxin Act which requires potency 
evaluation of bacterins prior to sale.  Currently, an in vitro potency assay employing a 
monoclonal antibody (ERHU-B60-91) is used to quantify the protective and highly 
conserved 64-66 kilodalton (kDa) protein of E. rhusiopathiae in erysipelas bacterins.  
Until now, the precise specificity of ERHU-B60-91 was unknown; through the use of a 
recombinant SpaA antigen of E. rhusiopathiae strain SE-9, it has been determined that 
that ERHU-B60-91 is specific for the protective domain of SpaA of E. rhusiopathiae.  
 
Keywords 
Erysipelothrix rhusiopathiae; surface protective antigen; swine erysipelas bacterin  
 
1. Introduction 
 The genus Erysipelothrix contains 23 separate serotypes which are divided into 
two distinct species, E. rhusiopathiae and E. tonsillarum, and two separate unclassified 
groups [1, 2].  Erysipelothrix rhusiopathiae is the only specie associated with causing the 
disease erysipelas in swine and less frequently in other animals [2, 3, 4, 5].  
Erysipelothrix rhusiopathiae also infects humans and is termed erysipeloid.  Outbreaks of 
erysipelas in swine herds can lead to great economic loss due to death or condemnation 
of carcasses at slaughter, and strict vaccination regimens have been put into place to 
avoid the disease [3].  Among the 16 serotypes classified as E. rhusiopathiae [2], 
serotypes 1a, 1b, and 2 are the most relevant in swine erysipelas [3, 6].  It has been found 
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that these three serotypes are cross-protective against each other, and in the United States, 
most commercial erysipelas bacterins are formulated with serotype 2 strains [3, 7, 8]. 
A cell surface component of E. rhusiopathiae has long been known to elicit 
protective antibodies against the specie.  In a report by Galán and Timoney [9], an 
approximately 64-66 kilodalton (kDa) membrane protein was implicated as the major 
protective antigen.  Makino et al. [10] later characterized the 64-66 kDa protein from the 
serotype 2 strain, Tama-96, and published the gene sequence under the name ‘surface 
protective antigen A’ (spaA).  Subsequent studies have focused on identifying the 
protective properties of the protein [11, 12, 13].  In a study by Imada et al. [12], a Sau3AI 
library of spaA was cloned from the serotype 1a strain, Fujisawa; the clones were 
expressed with a histidine hexamer tag in Escherichia coli, purified, and examined for 
their ability to protect mice and swine against challenge with virulent strains of               
E. rhusiopathiae serotypes 1 and 2.  One particular fusion protein, consisting of 342 
amino acids of the N-terminus, elicited complete protection by active immunization and 
it was hypothesized that the protective region of SpaA exists within the N-terminal two-
thirds of the protein.   
Recently, To and Nagai [13] confirmed Imada’s theory of a protective region of 
the Spa protein when they reported the detection of two additional Spa-types within 
Erysipelothrix.  The three Spa groups are distinguished based on amino acid sequence 
variation within a portion of the protein termed the protective domain, located between 
amino acids 29 through approximately 420.  Based on sequence analysis of Spas from 
several Erysipelothrix serotype reference strains, it was determined that SpaA is produced 
in serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 and N; SpaB is produced in serotypes 4, 6, 
11, 19 and 21; and SpaC is produced in the Erysipelothrix serotype 18.  
Realizing the importance of the 64-66 kDa protein in providing protection against 
erysipelas, the veterinary biologics regulatory arm of the United States Department of 
Agriculture, the Center for Veterinary Biologics (CVB), has developed a monoclonal 
antibody specifically recognizing the 64-66 kDa protein of E. rhusiopathiae [14]. The 
purpose of this antibody has been to quantify the protective protein in erysipelas bacterins 
in an in vitro potency assay [15].  The resulting monoclonal antibody, named ERHU-
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B60-91, has been found to passively protect both mice and swine against challenge with 
virulent E. rhusiopathiae of serotypes 1a and 2 [14], and is currently being used by the 
CVB and biologics manufacturers for in vitro potency testing of killed E. rhusiopathiae 
bacterins [16]. 
It is assumed that ERHU-B60-91 is specific for SpaA because it was produced 
against a serotype 2 E. rhusiopathiae strain, is specific for a 64-66 kDa protein, and is 
protective against virulent E. rhusiopathiae challenge.  Since the inception of ERHU-
B60-91 and the in vitro assay, much more is known about the 64-66 kDa protective 
protein of E. rhusiopathiae; however, the molecular specificity of the antibody has never 
been elucidated.  Because the CVB has become dependent upon ERHU-B60-91 for 
potency determination of commercial erysipelas bacterins, it is important to fully 
characterize the monoclonal antibody responsible for this regulation.  Therefore, the 
purpose of this study was to produce a recombinant SpaA antigen that can be used to 
verify the identity of the protein recognized by ERHU-B60-91 and implicate the region 
of the protein which is recognized. 
 
2.  Materials and Methods 
2.1 Bacterial strains, plasmids, and growth conditions 
Erysipelothrix rhusiopathiae strain SE-9 (serotype 2) was used in the production 
of E. rhusiopathiae standard reference bacterin IRP 529(05) as well as for cloning spaA. 
Erysipelothrix rhusiopathiae strain E1-6P (serotype 1a) was used for mouse challenges.  
Expression vector pQE-30 UA (Qiagen, Valencia, CA) was used to construct the 
recombinant SpaA (rSpaA) with an N-terminal histidine hexamer tag in the Escherichia 
coli host strain, M15 (Qiagen).  
Erysipelothrix rhusiopathiae were streaked for isolation and grown on 5% bovine 
blood agar at 37° C and propagated as previously described [13].  Briefly, a single colony 
was isolated from agar and inoculated into 10.0 mL filter-sterilized tryptose phosphate 
broth (pH 7.8) supplemented with 10.0 g/L proteose peptone no. 3 (Difco Laboratories, 
Detroit, MI) and 0.1% Tween 80 and grown with agitation for 20-24 hours at 37° C.  For 
E. rhusiopathiae challenge, overnight cultures were adjusted to 74.0 %T ± 0.2 in a 
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spectrophotometer set at 600 nm prior to preparing dilutions for injection in mice.  
Recombinant E. coli was grown on LB agar or LB broth supplemented with kanamycin 
(25 µg/mL) and carbenicillin (50 µg/mL) at 37° C.  
 
2.2 Whole cell antigen preparation 
Surface antigens of E. rhusiopathiae strain SE-9 were obtained by extraction as 
previously described [9].  Briefly, overnight broth cultures were centrifuged at 5,000 x g 
for 5 minutes to pellet the cells.  The supernatant was decanted, sterile filtered, and stored 
at -80° C.  The cells were washed twice with 5.0 mL sterile 20 mM Tris buffer (pH 7.6).  
The supernatant from the wash steps was decanted, filter sterilized, and stored at -80° C.  
The washed cells were resuspended in 0.5 mL sterile 20 mM Tris buffer (pH 7.6) 
containing 0.5% Triton X-100 (Sigma Co., St. Louis, MO) and incubated with agitation 
at 37° C for 60 minutes.  The samples were centrifuged at 9,000 x g for 5 minutes and the 
supernatant containing the surface antigens was decanted from the pellet and stored at       
-80° C.  Total cell lysates of E. coli strain M15 were obtained by growing a culture 
overnight in LB broth supplemented with kanamycin (25 µg/mL).  The cells were washed 
twice with 0.015 M phosphate-buffered saline (PBS, pH 7.2), resuspended in PBS, heated 
for 10 minutes at 70° C, and stored at -80° C. 
 
2.3 PCR amplification 
 Genomic DNA of E. rhusiopathiae strain SE-9 was purified from 1.0 mL of 
overnight culture using QIAamp® DNA Mini Kit (Qiagen).  Primers FwdNT-SE9, 5’-
AAT GAA CCA AAG GGG TAC-3’ and RevNT-SE9, 5’-AAC TGG CTT CTT TTG 
ATC-3’, corresponding to positions 6 to 23 and 1044 to 1061, respectively, were 
designed from the protective domain of spaA of E. rhusiopathiae strain SE-9 (GenBank 
accession AB024084) using Oligo 6 software (Molecular Biology Insights, Inc., Cascade, 
CO) and custom synthesized (Iowa State University DNA Facility, Iowa State University, 
Ames, IA).  Polymerase chain reaction was performed in a 50 μL reaction mixture that 
contained final concentrations of one unit Platinum® Taq DNA polymerase (Invitrogen, 
Carlsbad, CA), 1X reaction buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, and 0.2 μM each 
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primer.  Samples were subjected to initial denaturation at 94° C for 3 minutes; 30 cycles 
of denaturation at 94° C for 45 seconds, annealing at 55° C for 1 minute, and extension at 
72° C for 2 minutes; with a final extension at 72° C for 5 minutes.   
 
2.4 Cloning, expression, and purification of a recombinant fusion protein 
Polymerase chain reaction product was purified using the MinElute PCR 
purification kit (Qiagen) then ligated to the plasmid pQE-30 UA as shown in Figure 2.1.  
Recombinant histidine-tagged SpaA (rSpaA) was expressed in E. coli M15 and purified 
as recommended by the manufacturer (Qiagen) under denaturing conditions.  Briefly,  LB 
broth was inoculated at a 1:50 dilution with overnight culture of recombinant E. coli, 
grown at 37° C to mid-exponential phase (A600 = 0.6), and then induced with 1 mM IPTG 
for 4 hours with vigorous shaking.  Cells were harvested and resuspended in 6 M 
guanidine buffer (pH 8.0) at 3.0 mL/gram wet weight and shaken gently for an hour at 
room temperature to solublize the fusion protein.  The lysate was centrifuged at 10,000 x 
g for 30 minutes at room temperature then the fusion protein in the supernatant was filter 
sterilized and adsorbed on a nickel-nitrilotriacetic acid (Ni-NTA) agarose column.  The 
column was washed with 6 M guanidine buffer (pH 8.0), followed by 8 M urea buffer 
(pH 8.0) and 8 M urea buffer (pH 6.3).  The fusion protein was then eluted with 8 M urea 
buffer (pH 4.5) and dialyzed in 12-14,000 MWCO dialysis tubing against 0.015M PBS 
(pH 7.2). 
 
2.5 Sequencing 
 Plasmid DNA from 2.0 mL of overnight culture of recombinant E. coli was 
purified with the PureLink Miniprep kit (Invitrogen).  Both strands of DNA of cloned 
PCR product were sequenced on a Model 3730xl DNA Analyzer (Applied Biosystems, 
Carlsbad, CA) using a primer-walking procedure starting with vector sequencing primers 
recommended by the manufacturer (Qiagen). 
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2.6 Animals 
 CF-1 mice (Charles River Laboratories, Wilmington, MA) 8-10 weeks old, and 
specific pathogen-free (SPF) pigs (Northwoods Pork, Parkers Prairie, MN) 10-12 weeks 
old obtained from dams that were not immunized for the disease, were used. All animals 
were provided food and water ad libitum.  All management and experimental procedures 
were performed in accordance with the requirements of the USDA-Center for Veterinary 
Biologics-National Veterinary Services Laboratory Animal Care and Use Committee 
which conform to provisions of the Animal Welfare Act (Public Laws 85-544 and 
subsequent amendments).   
 
2.7 Mouse immunization and challenge 
 A 20,000 MWCO iCON concentrator tube (Thermo Scientific, Rockford, IL) was 
used to change the buffer of the rSpaA preparation from 0.015 M PBS (pH 7.2) to 0.85% 
saline.  Aggregated protein was sonicated three times at 50% duty cycle, 40 watts, 20 
kHz, on ice using an ultrasonic processor with microtip.  A BCA Protein Assay (Thermo 
Scientific) was used to estimate the total protein concentration of the buffer-exchanged 
rSpaA.  Following manufacturer’s instructions, rSpaA antigen was added to a vial of 
Sigma Adjuvant System (Sigma-Aldrich, St. Louis, MO) to achieve a 250 µg/mL antigen 
concentration.  Eight mice were injected subcutaneously with a 0.2 mL dose (50 µg/dose) 
in the left flank, while 15 mice were kept as nonvaccinated controls for 50% lethal dose 
(LD50) estimation following the method of Reed and Muench [17].  A booster vaccination 
was prepared three weeks later and administered in the right flank area.  Two weeks after 
booster, all mice were challenged subcutaneously with E. rhusiopathiae strain E1-6P and 
monitored 10 days for death.  
 
2.8 Preparation of pig antiserum 
Eight pigs were immunized subcutaneously with 2.0 mL E. rhusiopathiae 
standard reference bacterin IRP 529(05) twice at two week intervals.  Three weeks after 
the second immunization, sera were collected from all eight pigs and pooled. 
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2.9 SDS-PAGE and Western blot 
The BCA Protein Assay (Thermo Scientific) was used to estimate the total protein 
of purified rSpaA, E. rhusiopathiae SE-9 surface antigen extract, and E. coli M15 whole 
cell extract.  Aliquots of each sample were mixed with 1X NuPAGE® LDS buffer 
(Invitrogen) to attain a protein concentration of approximately 0.2 μg/µL of purified 
recombinant protein and 3.0 µg/µL of surface protein or whole cell protein.  The samples 
were then heated for 10 minutes at 70° C, and 10 µL of sample per well was separated in 
duplicate NuPAGE® Novex Bis-Tris 4-12% gradient gels (Invitrogen) in MOPS buffer 
under reducing conditions.  Gels were assembled into a sandwich with nitrocellulose 
membranes and transferred in an X-Cell IIтм Blot Module (Invitrogen).  Membranes were 
blocked in 5% skim milk in 20 mM Tris—500 mM NaCl—0.5% Tween 20 (TTBS, pH 
7.5) and incubated with agitation at room temperature for 60-90 minutes.  Membranes 
were then immersed in a 1:5,000 dilution of monoclonal antibody ERHU-B60-91 or a 
1:100 dilution of swine serum prepared in 5% skim milk-TTBS and incubated with 
agitation at room temperature for 60-90 minutes.  After four 5 minute washes in TTBS, 
the membranes were incubated for 60-90 minutes in goat anti-mouse IgG-horseradish 
peroxidase conjugated antibody (heavy and light chains; Kirkegaard & Perry 
Laboratories, Gaithersburg, MD) or goat anti-pig IgG-horseradish peroxidase conjugated 
antibody (heavy and light chains; Jackson ImmunoResearch, West Grove, PA) diluted 
1:5,000 in 5% skim milk-TTBS .  Following four 5 minute washes in TTBS, bound 
antibodies were detected with 3,3’,5,5’-tetramethylbenzidine (TMB) and TMB 
Membrane Enhancer (Kirkegarrd & Perry Laboratories).   
Separated total protein of each sample was visualized by staining a duplicate 
SDS-PAGE gel with SimplyBlueтм SafeStain (Invitrogen) or by staining a duplicate 
nitrocellulose membrane with AuroDyeтм Forte (GE Healthcare, Buckinghamshire, UK). 
 
2.10 ELISA 
A titration of the purified rSpaA and ERHU-B60-91 was performed by indirect 
ELISA.  Wells of an Immulon 2 high binding plate (Thermo Scientific, Waltham, MA) 
were coated with 100 µL of purified rSpaA, diluted 5 µg/mL, 7.5 µg/mL, 10 µg/mL, and 
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15 µg/mL in 0.05 M carbonate-bicarbonate buffer (pH 9.6).  After one hour incubation at 
37° C, the plate was washed three times with 300 µL PBS-0.05% Tween 20 (PBST, pH 
7.2).  Each well was blocked with 100 µL of 5% skim milk-PBS for one hour at 37° C.  
The plate was washed and two-fold dilutions of ERHU-B60-91 were made across the 
plate, starting with a 1:16,000 dilution in 5% skim milk-PBST.   The plates were 
incubated for one hour at 37° C, washed, and then 100 µL of a 1:5,000 dilution of goat 
anti-mouse IgG-horseradish peroxidase conjugated antibody (heavy and light chains; 
Kirkegaard & Perry Laboratories) in 5% skim milk-PBST was added to each well.  The 
plates were incubated for one hour, washed, and then 100 µL TMB substrate (Kirkegaard 
& Perry Laboratories) was added to each well.  The reaction was terminated after 10 
minutes by adding 100 µL 2.5 M sulfuric acid to each well.  The absorbance was read at 
450 nm. 
 
3. Results 
3.1 Nucleic acid sequencing 
DNA sequences were assembled using the SeqMan program of the DNASTAR 
software package (DNASTAR Inc., Madison, WI).  The nucleic acid sequence of the 
cloned PCR insert was a 100% identity match to positions 6 through 1061 of the spaA 
sequence of strain SE-9 (GenBank accession AB024084).  The nucleic acid sequence was 
translated into amino acid sequence using EMBOSS Transeq [18].  The deduced amino 
acid sequence of the PCR insert in the pQE-30 UA vector was examined and found to be 
in correct order (Figure 2.2). 
 
3.2 Mouse protection assay 
 Six of eight mice, immunized twice with 50 µg/dose of purified rSpaA in Sigma 
Adjuvant System, survived subcutaneous challenge with 681 LD50 of virulent                 
E. rhusiopathiae strain E1-6P (Table 2.1).  
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3.3 SDS-PAGE and Western blot 
 Monoclonal antibody ERHU-B60-91 and antiserum produced in pigs against       
E. rhusiopathiae bacterin IRP 529(05) reacted well with the 66 kDa intact SpaA in the  
SE-9 surface antigen preparation.  ERHU-B60-91 and the antiserum also detected the 
purified rSpaA, which showed the predicted molecular weight of 42 kDa.  There was no 
apparent cross-reaction of the swine serum with E. coli M15 antigens (Figure 2.3). 
 
3.4 Indirect ELISA 
 The titration of rSpaA and ERHU-B60-91 in the indirect ELISA revealed high 
reactivity of the monoclonal antibody for the antigen (Figure 2.4).  At a dilution of 
1:2,048,000, the monoclonal antibody sensitively detected the recombinant protein at all 
concentrations. 
 
4. Discussion 
This study has shown that monoclonal antibody ERHU-B60-91 is specific for the 
protective domain of SpaA.  A recombinant antigen, designed from the protective domain 
of spaA from the E. rhusiopathiae strain SE-9, was shown to be protective in mice, and 
was specifically recognized by the monoclonal antibody in Western blotting.  ERHU-
B60-91 also reacted strongly to the rSpaA antigen in an indirect ELISA.   
It is accepted that Spa proteins are potent protective antigens against                    
E. rhusiopathiae infection [9, 11, 12, 13].  Recently it has been reported that SpaA is the 
major Spa-type of serotypes 1a, 1b, and 2 [13] which are most commonly implicated in 
swine erysipelas [3].  The protective domain of SpaA lies between amino acids 29-414 
[13] and it is believed that this area alone can induce highly protective antibodies against 
E. rhusiopathiae infection [12].  Because it has been shown that ERHU-B60-91 
recognizes an epitope that lies within the protective domain of SpaA, its use to measure 
the protective antigen in swine erysipelas bacterins is substantiated.   
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Figure 2.1 Map of pQE-30 UA construct illustrating the UA overhangs which properly 
align the PCR product insert. 
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(A) 
atg
aatgaaccaaaggggtaccaaagtttcgaagcagtgaatgaagagattaactcgattgta 
agaggatcgcatcaccatcaccatcacggatcccacgtgatatcctcaatcgcttcU 
agtgaacttaaacatgaaggaatgagtcttcaaaacattcaccatatgtttaaacaaagc 
atccaaaacctagcaactagaatcggctacagaagttttatgcaggatgctatgtatctt 
gaaaattttgaaagattaacgattcctgaacttgatgaagcatacgttgatttactcgtg 
aattacgaggtgaaacaccgtattttagtaaaatatgaagataaagttaaaggtagagct 
ccattagaagcatttatagttcctctaagaaatagaattcgtagtatgaatgaaattgct 
gcagaagtaaattatttacctgaagcgcatgaggatttcttagtttcagattcaagcgag 
tataatgacaaactaaataatatcaactttgctttgggtctaggggtcagcgagtttatt 
gactataaccggctcgaaaatatgatggaaaaagaaattcatccattgtatcttgaactt 
tatgctatgcggagaaatcgccaaattcaagttgtaagagatgtatatccaaacttggaa 
cgtgcgaacgcggttgttgaatccttaaagacaattaaagatataaaacaaagagagaag 
aaactacaggaacttcttgaaatttatatccaaagaagtggagatgttcgaaaaccagat 
gtactccaacgatttattggaaaatatcaatcagtagttgatgaagaaaaaaataaactt 
caagattatttagaatcagatatttttgattcatatagtgtggatggcgagaaaataaga 
aataaagaaattacactcatcaatagagatgcatacttatctatgatttacagagctcaa 
tcgatttcggaaattaagacgattcgtgcagatttagaatcacttgtcaaatcattccaa 
aatgaagaaagtgattctaaagtagagcctgaaagtcccgttaaagtagaaaaaccagtt 
gataaagaaaaacctaaagatcaaaagaagccagttAgaagcgat
 
tga 
 
 
 
(B) 
MRGSHHHHHHGSHVISSIASNEPKGYQSFEAVNEEINSIVSELKHEGMSLQNIHHMFKQ
SIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKG
RAPLEAFIVPLRNRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVS
EFIDYNRLENMMEKEIHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTIKDIK
QREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVD
GEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSFQNEESDSKVEPESPV
KVEKPVDKEKPKDQKKPVRSD 
 
 
 
 
 
 
 
 
 
Figure 2.2 (A) The nucleic acid sequence of the cloned spaA PCR insert, flanked by 
pQE-30 UA vector sequence.  The bolded letters are part of the pQE-30 UA vector 
sequence, the underlined text indicating the start codon and stop codon, and the capital 
letters specifying the U and A overhangs.  (B) The deduced amino acid sequence of the 
expressed recombinant protein.  
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Figure 2.3 (Gel A) SDS-PAGE gel stained with SimplyBlueтм SafeStain; (Blot A) 
immunoblot detection with ERHU-B60-91; (Blot B) immunoblot detection with immune 
swine serum.
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Figure 2.4 Indirect ELISA titration of rSpaA (across the plate in rows) and ERHU-B60-91 (across the plate in columns).
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rSpaA 
2.466 2.349 2.133 1.867 1.454 1.003 0.567 0.302 0.151 0.118 0.071 0.086 
2.480 2.368 2.181 1.872 1.434 0.998 0.593 0.292 0.157 0.102 0.074 0.079 
7.5 
µg/mL 
rSpaA 
2.533 2.465 2.273 1.872 1.649 1.049 0.672 0.333 0.173 0.130 0.091 0.056 
2.628 2.434 2.185 2.009 1.624 1.087 0.661 0.362 0.163 0.138 0.102 0.047 
10.0 
µg/mL 
rSpaA 
2.569 2.456 2.171 2.144 1.794 1.258 0.783 0.426 0.212 0.141 0.104 0.053 
2.619 2.522 2.398 2.176 1.795 1.248 0.795 0.486 0.246 0.148 0.086 0.046 
15.0 
µg/mL 
rSpaA 
2.615 2.459 2.272 2.129 1.665 1.110 0.634 0.380 0.216 0.123 0.074 0.038 
2.577 2.438 2.334 2.049 1.545 1.104 0.712 0.325 0.197 0.125 0.087 0.038 
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Table 2.1 Mouse protection assay results.  A group of eight mice were vaccinated 
twice with 50 µg rSpaA then challenged with E. rhusiopathiae strain E1-6P.  
Nonvaccinated controls were given various dilutions of strain E1-6P challenge to 
determine the LD50 dose of the challenge.  Vaccinated mice received 681 LD50 
doses of E1-P6 challenge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Challenge dose Live/total in group 
rSpaA vaccinates  0.2 mL 10-5 6/8 
Nonvaccinated controls 0.2 mL 10-7 0/5 
Nonvaccinated controls 0.2 mL 10-8 3/5 
Nonvaccinated controls 0.2 mL 10-9 5/5 
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CHAPTER 3.  A SURVEY OF ERYSIPELOTHRIX RHUSIOPATHIAE STRAINS 
FOR THE POSSESSION OF SpaA AND EVALUATION OF A SWINE 
ERYSIPELAS BACTERIN FOR CROSS-PROTECTION  
 
A paper to be submitted to Vaccine 
 
Alaina L. Ingebritson 
 
Abstract 
 A collection of Erysipelothrix rhusiopathiae swine, fish, and cetacean strains 
representing all 16 serotypes were analyzed for their possession of the three recognized 
spa-types: spaA, spaB, and spaC.  It was found that spa-type and serotype were not 
associated, especially in strains originating from fish.  Several strains were not reactive in 
polymerase chain reaction (PCR) assays with primers specific for the three accepted spa-
types, indicating that genetic variation of the spa has occurred or the existence of novel 
spa-types in these strains.  In addition, several strains of serotypes reported to express 
spaB were reactive in Western blotting with a monoclonal antibody that is specific for 
SpaA. A cross-protection study utilizing mice immunized with a serotype 2 SpaA-type 
swine bacterin demonstrated superior protection against isolates exhibiting a single 
homologous spa, but variable protection against those possessing heterologous spa or 
more than one spa-type.   
 
Keywords 
Erysipelothrix rhusiopathiae; surface protective antigen; erysipelas; protective immunity; 
cross-protection  
 
1. Introduction 
Erysipelas is a bacterial disease characterized by urticarial diamond-shaped 
lesions which can quickly progress to an acute septicemic infection or death.  Chronic 
erysipelas usually follows an acute infection where self-sustaining, destructive 
pathological changes in the heart valves and joints produce endocarditis and arthritis, 
respectively [1].  The disease has a great economic and epidemiological impact on animal 
production and handling worldwide, with outbreaks of the disease being reported most 
often in swine and turkey production farms and marine aquaria.  
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The genus Erysipelothrix contains two accepted species, E. rhusiopathiae which 
include serotypes 1a, 1b, 2, 4, 5, 6, 8, 9, 11, 12, 15, 16, 17, 19, 21 and N; and                  
E. tonsillarum containing serotypes 3, 7, 10, 14, 20, 22 and 23 [2, 3].   Two unclassified 
Erysipelothrix groups representing serotypes 13 and 18 are also recognized [3].  It has 
been shown that only E. rhusiopathiae is virulent in swine [3, 4] and killed and 
attenuated live vaccines are used to prevent the disease.  Bacterins developed for the 
prevention of erysipelas in swine are formulated with strains of serotype 2 which provide 
cross-protection against serotypes 1a, 1b, and 2, the most important serotypes in swine [5, 
6]. Other susceptible animal species, such as marine mammals, also rely on the swine 
strain bacterin formulations for protection [7, 8]; despite the fact that the most prevalent 
serotypes of cetacean clinical erysipelas have not been identified [7] and protection 
elicited by swine strain bacterins may not be adequate. 
It has been determined that the approximately 64-66 kilodalton (kDa) membrane 
protein, surface protective antigen A (SpaA), of E. rhusiopathiae plays a vital role in 
conferring immunological protection against the specie [9, 10, 11].  Recently, two 
additional types of spa-related genes were detected within E. rhusiopathiae and an 
unclassified serotype 18 of the genus Erysipelothrix [12].  Through amino acid sequence 
analysis, it was found that SpaA is produced in serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17 
and N; SpaB is produced in serotypes 4, 6, 11, 19 and 21; and SpaC is produced in the 
unclassified serotype 18.  The three molecular groups are distinguished based on the 
amino acid sequence of the protective domain and are considered antigenically different 
based on reactions with heterologous polyclonal antiserum in immunoblot and active 
immunization experiments in mice. 
Because the Spa family of proteins is considered to be the major protective 
antigen of E. rhusiopathiae [13, 14], it is important to recognize the Spa-type possessed 
by strains used in commercial erysipelas bacterins, especially when used in animal 
species other than swine which may not be adequately protected by the particular Spa-
type represented.  The objectives of this study were to determine whether Spa-type is 
confined to the specific group of Erysipelothrix serotypes as previously reported [12], 
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and to establish whether a bacterin composed of a swine strain serotype 2 expressing 
SpaA can protect mice against a variety of cetacean and fish strains of known Spa-type.   
 
2.  Materials and Methods 
2.1 Bacterial strains, growth conditions, and challenge preparation. 
Erysipelothrix rhusiopathiae strains used in this study are listed in Table 3.1. 
Erysipelothrix rhusiopathiae swine strains were serotyped at the USDA National Animal 
Disease Center or National Veterinary Services Laboratory (Ames, IA) and fish and 
cetacean strains were serotyped at the Veterinary Diagnostic Laboratory, Iowa State 
University College of Veterinary Medicine (Ames, IA). 
Cultures were streaked for isolation and grown on 5% bovine blood agar at 37° C 
and propagated as previously documented [12].  Briefly, a single colony was isolated 
from agar and inoculated into 10.0 mL filter-sterilized tryptose phosphate broth (pH 7.8) 
supplemented with 10.0 g/L proteose peptone no. 3 (Difco Laboratories, Detroit, MI) and 
0.1% Tween 80 and grown with agitation for 20-24 hours at 37° C.   
Strains used for testing in mice were Piquet, Immiayuk, Quitz, Naluark, Kayavak, 
Large Herring 182, and Large Herring 911.  Overnight cultures were adjusted to 74.0 %T 
± 0.2 in a spectrophotometer set at 600 nm prior to preparing dilutions for injection in 
mice. 
 
2.2 PCR amplification 
 Genomic DNA of E. rhusiopathiae strains was purified from 1.0 mL of overnight 
culture using QIAamp® DNA Mini Kit (Qiagen, Valencia, CA).  The following primers 
were designed from the protective domain of spaA of E. rhusiopathiae strain Fujisawa 
(GenBank accession AB019124) using Oligo 6 software (Molecular Biology Insights, 
Inc., Cascade, CO) and custom synthesized (Iowa State University DNA Facility, Iowa 
State University, Ames, IA):  spaA2F, 5’-CCA AAG GGG TAC CAA AGT T-3’, 
corresponding to position 259-277, and spaA2R, 5’-GAT TCG GGT TTT GAT TGA-3’, 
corresponding to position 1328-1311.  PCR was performed in a 50 μL reaction mixture 
that contained final concentrations of one unit Platinum® Taq DNA polymerase 
45 
 
(Invitrogen, Carlsbad, CA), 1X reaction buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, and 0.2 
μM each primer.  Samples were subjected to initial denaturation at 94° C for 5 minutes; 
30 cycles of denaturation at 94° C for 30 seconds, annealing at 58° C for 30 seconds, and 
extension at 72° C for 1 minute; with a final extension at 72° C for 7 minutes.   
The following primers were synthesized (Iowa State University DNA Facility) 
and used in PCR assays according to previously described reports:  primer 1, 5’-ATG 
AAA AAG AAA AAA CAC CTA-3’, and primer 2, 5’-CTA TTT TAA ACT TCC ATC 
GTT-3’, were used to amplify whole spaA [12]; primer 3, 5’-ATG AAA AAG AAA 
AAA CAC CTA TTT CCG AAA GTA-3’, and primer 4, 5’-CTA TTT TAA ACT TCC 
ATC GTT CTT AAA TGC ATA-3’, were used to amplify whole spaB or spaC [12]; and 
ERY-1F, 5’-ATC GAT AAA GTG TTA TTG GTG G-3’, and ERY-2R, 5’-CGA GTG 
TGA ATC CGT CGT CTC-3’, were used to verify the species of Erysipelothrix strains 
[15]. 
 
2.3 Sequencing of the spa protective domain 
A 1,070 base pair (bp) fragment of the protective domain of spaA from genomic 
DNA of E1-6P, Immiayuk, Piquet, Large Herring 182, and Large Herring 911 was 
amplified by PCR with primer set spaA2F/R.  The PCR product from each strain was 
purified using the MinElute® PCR purification kit (Qiagen) and cloned using the TOPO 
TA Cloning® Kit for Sequencing (Invitrogen) following manufacturer’s instructions.   
Purified plasmids were obtained using the PureLink Miniprep kit (Invitrogen) and both 
strands of DNA of cloned PCR products were sequenced on a Model 3730xl DNA 
Analyzer (Applied Biosystems, Carlsbad, CA) using a primer-walking procedure starting 
with vector primers T3 and T7.  DNA sequences were assembled using the SeqMan 
program of the DNASTAR software package (DNASTAR Inc., Madison, WI) and 
translated into amino acid sequence using EMBOSS Transeq [16].  Amino acid 
sequences were aligned with Spa sequences of E. rhusiopathiae strains Fujisawa 
(GenBank accession AB019124), SE-9 (AB024084), Dolphin E-1 (AB238212), and 
Erysipelothrix strain 715 (AB238210) using the T-Coffee multiple sequence alignment 
tool [17]. 
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2.4 Antigen preparation  
Surface antigens of E. rhusiopathiae were obtained by extraction as previously 
described [13].  Briefly, overnight broth cultures were centrifuged at 5,000 x g for 5 
minutes to pellet the cells.  The supernatant was decanted, sterile filtered, and stored at    
-80° C.  The cells were washed twice with 5.0 mL sterile 20 mM Tris buffer (pH 7.6).  
The supernatant from the wash steps was decanted, filter sterilized, and stored at -80° C.  
The cells were resuspended in 0.5 mL sterile 20 mM Tris buffer (pH 7.6) containing 
0.5% Triton X-100 (Sigma Co., St. Louis, MO) and incubated with agitation at 37° C for 
60 minutes.  The samples were centrifuged at 9,000 x g for 5 minutes and the supernatant 
containing the surface antigens was decanted from the pellet and stored separately at        
-80° C. 
 
2.5 SDS-PAGE and Western blot 
Total protein of each E. rhusiopathiae antigen preparation was estimated using 
the BCA Protein Assay (Thermo Scientific, Rockford, IL).  Approximately 50 μg of 
protein per sample per well was separated in NuPAGE® Novex Bis-Tris 4-12% gradient 
gels (Invitrogen) in MOPS buffer under reducing conditions.  An X-Cell IIтм Blot Module 
(Invitrogen) was used to transfer separated proteins to nitrocellulose membranes.  
Membranes were immersed in 20 mM Tris—500 mM NaCl—0.5% Tween 20 (TTBS, pH 
7.5) and incubated with agitation at room temperature for 60 to 90 minutes, followed by a 
60 to 90 minute incubation with a 1:5,000 dilution of monoclonal antibody ERHU-B60-
91 [18] in TTBS.  After four 5 minute washes in TTBS, the membranes were incubated 
for 60-90 minutes in goat-anti-mouse IgG-horseradish peroxidase conjugated antibody 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) diluted 1:5,000 in TTBS.  
Membranes were washed, and bound antibodies were detected with 3,3’,5,5’-
tetramethylbenzidine (TMB) and TMB Membrane Enhancer (Kirkegaard and Perry 
Laboratories).   
Separated total protein of each sample was visualized by staining duplicate SDS-
PAGE gels with SimplyBlueтм SafeStain (Invitrogen) or by staining duplicate 
nitrocellulose membranes with AuroDyeтм Forte (GE Healthcare, Buckinghamshire, UK). 
47 
 
2.6 Animals  
 CF-1 mice (Charles River Laboratories, Wilmington, MA) 8-10 weeks old were 
used for each experiment.  They were provided food and water ad libitum.  All 
management and experimental procedures were performed in accordance with the 
requirements of the USDA Center for Veterinary Biologics-National Veterinary Services 
Laboratory Animal Care and Use Committee which conform to provisions of the Animal 
Welfare Act (Public Laws 85-544 and subsequent amendments).   
 
2.7 Erysipelothrix rhusiopathiae strain lethality testing  
The mouse 50% lethal dose (LD50) of each E. rhusiopathiae strain was 
determined by inoculating groups of mice subcutaneously with 0.1 mL of a 10-fold 
dilution of overnight culture.  The mice were housed in isolation and observed for 10 
days for clinical signs and mortality.  The LD50 was calculated for each strain following 
the method of Reed and Muench [19]. 
 
2.8 Cross-protection studies 
A working stock of E. rhusiopathiae standard reference bacterin IRP 529(05) was 
prepared in sterile 0.85% saline as recommended by Center for Veterinary Biologics 
Notice 08-11 [20].  A 1:30 dilution was prepared from the working stock and used to 
vaccinate a group of 80 mice with a single subcutaneous 0.2 mL dose.  Fifteen days after 
vaccination, a cross protection study was performed per E. rhusiopathiae strain by 
challenging groups of 10-12 vaccinated mice.  Groups of 10 nonvaccinated mice were 
used as controls and to calculate LD50 per strain.  The mice were housed in isolation and 
clinical signs and mortality were observed for 10 days.  Challenge doses, given 
subcutaneously in 0.1 mL, were E1-6P, 1,242 LD50; Piquet, 749 LD50; Immiayuk, 425 
LD50; Quitz, 316 LD50; Naluark, 262 LD50; Kayavak, 425 LD50; and Large Herring 182, 
368 LD50.   
 
 
 
48 
 
2.9 Statistical methods 
 Live-versus-dead numbers in the cross-protection studies were compared by the 
Fisher exact test using a two-tailed p-value [21].  
 
3.  Results 
3.1 Polymerase chain reaction 
 Polymerase chain reaction (PCR) was performed using primers to detect whole 
spaA, whole spaB and spaC, and the protective domain of spaA from 83                         
E. rhusiopathiae strains, of which 57 were swine strains representing all 16 serotypes; 20 
were fish isolates representing 10 serotypes; and six were cetacean strains representing at 
least five serotypes (Table 3.2).  
Using primers 1/2 and primers spaA2/F, designed to amplify whole spaA and the 
protective domain of spaA, respectively, all swine strains of serotypes 1a, 1b, 2, 9, 15, 
16, 17, and N produced amplification products of appropriate size.  Half of the swine 
strains representing serotypes 5, 8, and 12 produced amplicons with both spaA-specific 
primer sets, while no gene amplification was detected in swine strains of serotypes 4, 6, 
11, 19, and 21 for either primer set.   
Production of amplification products was variable with fish strains of all 
serotypes using the spaA-specific primer sets.  Only strains of serotypes 1b and 2 
consistently produced amplification products of expected size from both primers, while 
five of 11 fish strains representing the serotypes 5, 6, 8, and 21 produced amplification 
products from both spaA-specific primer sets.  Single strains of serotype 4 and serotype 
21 produced an amplification product from the whole spaA primers, but a product was 
not produced by the spaA protective domain primers. Three fish strains representing 
serotype 1a, 12, and 15 respectively, failed to produce an amplicon from either spaA-
specific primer set.  Only two of six cetacean strains, a serotype 2 Beluga whale strain 
and a nontypeable dolphin strain, produced amplification products of expected size from 
both spaA-specific primer sets. 
 The spaB/C primer set was used to amplify those genes from all E. rhusiopathiae 
fish and cetacean strains as well as swine strains which did not react with the spaA-
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specific primers.  Six of seven fish strains representing serotypes 4, 6, and 21 produced 
an amplicon of approximately 1880 bp from the primer set.  No amplification product 
was produced from any swine or cetacean strain using the spaB/C-specific primer set.   
A PCR assay utilizing the E. rhusiopathiae species-specific primers was used to 
verify the species identification of the strains nonreactive with any of the spa primers.  
An amplicon 2,210 bp in length was produced from each strain, confirming that these 
strains were E. rhusiopathiae. 
 
3.2 Protective domain sequence comparison 
 DNA sequences of the protective domain of spaA from five strains of                 
E. rhusiopathiae were sequenced, translated into amino acid sequences, and compared to 
sequences representing each Spa-type published in GenBank.  Strains were chosen based 
on PCR reactions with spaA-specific primers and include swine strain E1-6P (serotype 
1a); Beluga whale strain Immiayuk (serotype 2); a nontypeable Pacific white-sided 
dolphin strain Piquet; and two fish strains, Large Herring 182 (serotype 6) and Large 
Herring 911 (serotype 21).  The deduced amino acid sequences from these selected 
strains were 98.2% to 99.7% identical to the 342 amino acid sequence of the protective 
domain of SpaA of strain Fujisawa (AB019124) and 99.1% to 99.7% identical to that of 
strain SE-9 (AB024084), as shown in Figure 3.1.    
 
3.3 Expression of spa and reactivity to a SpaA-specific monoclonal antibody 
All 83 E. rhusiopathiae strains were examined by SDS-PAGE for their expression 
of a 64-66 kDa protein and its interaction with the monoclonal antibody, ERHU-B60-91, 
shown to be specific for the protective domain of SpaA (data not shown).  In SDS-PAGE 
analysis, all 83 strains produced a 64-66 kDa protein, but only those strains which 
produced an amplicon in PCR with the spaA protective domain primers were recognized 
by ERHU-B60-91 (Table 3.2).   
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3.4 Strain lethality testing 
 Pathogenicity data for each strain are listed in Table 3.3.  The fish and cetacean 
strains appeared nearly equal in their pathogenicity in mice except for strain Large 
Herring 911 (serotype 21) which did not kill mice. Based on the LD50 dose, swine strain 
E1-6P (serotype 1a) was more pathogenic for mice than the fish and cetacean strains 
tested. 
 
3.5 Cross-protection experiment 
 The experiment was designed to examine whether the swine strain serotype 2 
SpaA-type E. rhusiopathiae standard reference bacterin IRP 529(05) could protect mice 
equally against challenge with cetacean and fish strains of various serotypes and Spa-
types compared to the serotype 1a SpaA-type swine strain, E1-6P (Figure 3.2). 
 Within four days after challenge with E1-6P, all nonvaccinated control mice died 
while all vaccinated mice survived 10 days when the experiment was terminated.  The 
difference between the vaccinated group and the nonvaccinated group was significant  
(P < 0.0001). 
 Bacterin IRP 529(05) induced complete protection (100%) against challenge with 
the SpaA-type dolphin strain Piquet (nontypeable) and the SpaA-type Beluga whale 
strain Immiayuk (serotype 2).  No significant difference was exhibited in the ability of 
the bacterin to protect mice against Piquet and Immiayuk compared to the E1-6P 
challenge (P = 1.0000).  Of 12 vaccinated mice challenged with SpaA-type Large 
Herring 182 (serotype 6), only two survived, indicating a significant difference compared 
to the results of the E1-6P challenge (P < 0.0001).  
Upon challenge with the non-SpaA Beluga whale strain Naluark (nontypeable), 
seven of 10 vaccinated mice survived, indicating that partial protection was induced 
compared to the  E1-6P challenge (P = 0.2105).  The ability of the reference bacterin to 
protect against challenge of the other non-SpaA-type strains showed significant 
differences compared to the E1-6P challenge.  Four of 10 vaccinated mice challenged 
with dolphin strain Quitz (serotype 2, 15) survived (P = 0.0108) while none of the 12 
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vaccinated mice challenged with Beluga whale strain Kayavak (serotype 5) survived     
(P < 0.0001).   
 
4. Discussion 
The Spa proteins of E. rhusiopathiae are cell membrane-bound and recognized as 
the major protective antigen of the species [13, 14].  This present study investigated a 
wide range of E. rhusiopathiae strains isolated from swine, fish, and cetacean species and 
found i) that spa-type is not absolutely associated with serotype, especially in those 
strains isolated from fish; ii) that genetic variation of spa may occur within strains and/or 
more spa-types may exist in addition to the three currently accepted groups; iii) that a 
single E. rhusiopathiae strain may possess more than one spa-type.  
 SpaA was first characterized by Makino et al. [9] and Shimoji et al. [11] when 
investigating the immunodominant 64-66 kDa protein of the E. rhusiopathiae strains 
Tama 96 (serotype 2) and Fujisawa (serotype 1a), respectively.  While investigating the 
prominence of the SpaA, Makino surveyed reference strains of each E. rhusiopathiae 
serotype using a SpaA-specific monoclonal antibody in immunoblot and enzyme-linked 
immunosorbent assays (ELISA).  The protein was found in 11 of the 16 serotypes (1a, 1b, 
2, 5, 8, 9, 12, 15, 16, 17, and N), with only a weak signal detected in the five remaining 
serotypes (4, 6, 11, 19, and 21).  While performing active immunization experiments with 
recombinant portions of SpaA and passive protection trials with specific antiserum in 
mice, Shimoji identified the N-terminal two-thirds of the protein as possessing the 
epitope(s) responsible for eliciting protection.  
Recently, To and Nagai [12] reported the detection of two additional 
Erysipelothrix Spa-types, SpaB and SpaC.  Based on amino acid sequence analysis of 
Spa from single reference strains representing each serotype, it was determined that SpaA 
is produced by serotypes 1a, 1b, 2, 5, 8, 9, 12, 15, 16, 17, and N; SpaB is produced by 
serotypes 4, 6, 11, 19, and 21; and SpaC is produced by Erysipelothrix serotype 18.  
Alignment of the amino acid sequences representing each Spa group revealed distinct 
differences within the protective domain of the protein.  Immunoblot analysis showed 
strong reaction between purified SpaA, SpaB, and SpaC and homologous antiserum and 
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weak reactions with heterologous serum.  Similar cross-reactivity was observed in mouse 
protection studies where complete protection was observed against homologous Spa-type 
challenge but variable protection was obtained against heterologous challenge.  
In contrast to the studies reported by Makino et al. [9] and To and Nagai [12] 
which evaluated one strain per serotype, this study evaluated several E. rhusiopathiae 
strains per serotype.  These strains were analyzed by PCR for the possession of whole 
spaA, the protective domain of spaA, and whole spaB and spaC.  Fourteen strains of 
serotypes described as possessing spaA, including, five swine strains representing 
serotypes 5, 8, and 12; six fish strains representing serotypes 1a, 5, 8, 12, and 15; and 
three cetacean strains representing serotypes 8, 5, and 2/15 were non-reactive with either 
set of spaA-specific primers.  Western blot verified that these 14 strains lacked 
expression of spaA when the SpaA protective domain-specific monoclonal antibody, 
ERHU-B60-91, failed to detect the protein. Attempts were made to amplify spaB and 
spaC gene products from these 14 strains in PCR but those assays also yielded no results.   
The inability to detect spaA or its expression product in these particular strains 
indicates that spa-type and serotype are unrelated as suggested by To and Nagai [12].  
Either genetic variation of spaA had occurred in these 14 strains or they simply do not 
possess a spa that can be identified as one of the three currently accepted types.   The 
observation that spa-type and serotype are not absolutely associated was further 
supported by the fact that, in this study, four fish strains representing serotypes 6 and 21 
produced amplicons of correct size in PCR using both spaA-specific primer sets.  The 
expression of spaA from these strains was verified by Western blot when each produced 
an approximately 65 kDa protein that was detected by ERHU-B60-91.  To further 
investigate the identity of the spa possessed by these strains, PCR products resulting from 
amplification with the spaA protective domain primers were sequenced.  The DNA 
sequences were translated into amino acid sequences and aligned.  Each showed high 
sequence identity to the SpaA of strain Fujisawa.  This demonstrates that                        
E. rhusiopathiae serotypes 6 and 21, previously described as possessing spaB, can 
possess and express spaA, thus providing evidence that spa-type and serotype are not 
absolutely associated.   
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 In this study, primers designed to amplify spaB and spaC [12] were used in PCR 
with all strains of serotypes 4, 6, 11, 19, and 21, all fish and cetacean strains, as well as 
strains non-reactive with spaA-specific primers.  Serotype reference strains previously 
reported as producing a product in PCR with these primers failed to produce an 
amplification product in this study’s experiments.  Great care was taken to exactly follow 
the described protocol and several assays were performed to reproduce the published 
work, but to no avail.  However, the spaB/C PCR assay did prove successful with six fish 
strains representing serotypes 4, 6, and 21, which produced amplicons of expected size.  
From these results, it can only be estimated that some genetic variation has occurred 
between this laboratory’s serotype reference strain isolates and those possessed by To and 
Nagai [12], which has prevented the spaB/C primers from annealing effectively.  
As of yet, E. rhusiopathiae strains have only been described as possessing a 
single spa-type.  In this study, three fish strains produced amplicons of expected size in 
each of the three spa-specific PCR assays and two fish strains produced amplicons with 
the primer sets designed to amplify whole spaA and both whole spaB and –C.  These 
results raise the possibility that a single E. rhusiopathiae strain may possess more than 
one spa-type.   
So far from this study, it was been observed that E. rhusiopathiae serotypes can 
vary in their possession of spa-type, that a particular spa-type sequence may vary 
between strains or other novel spa-types exist, and a single E. rhusiopathiae strain can 
have more than one spa.  These observations have great significance in the use of 
erysipelas bacterins for cross-protection among different strains.  Nearly all commercial 
erysipelas bacterins are formulated with serotype 2 swine strains [6], and in this study, 
the only E. rhusiopathiae strains that consistently possessed and expressed a single spa- 
type were the 33 swine strains of serotypes 1a, 1b, and 2.  These strains all produced 
amplification products with the spaA-specific primer sets and expressed a protein 
recognized by ERHU-B60-91; demonstrating that spaA is highly conserved in serotypes 
most often implicated in clinical swine erysipelas.  This result may also explain the high 
rate of cross-protectiveness among these serotypes. 
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It has been reported by Lacave et al. [7] that an inactivated E. rhusiopathiae 
swine vaccine strain of serotype 2 can protect mice against challenge with dolphin strains 
of serotypes 1a, 2, 5, 15, and 21, but only partial protection was exhibited in the long 
term.  Because the Spa-status of the vaccine strain and the challenge strains were not 
reported in the study, the impact of Spa-elicited cross-protection is unknown.  In this 
present study, the Spa-type of the E. rhusiopathiae bacterin strain and challenge strains 
were determined prior to examining whether a SpaA-type swine strain could protect mice 
against challenge with cetacean and fish strains of homologous and heterologous Spa-
type.   
It has been shown that recombinant Spas elicit potent protection against challenge 
with homologous Spa-types and incomplete protection against heterologous Spa-types 
[12], so in this study, complete protection against those strains possessing a single 
homologous SpaA was not surprising.  What was interesting, however, was that 
protection against Large Herring 182, a serotype 21 fish strain possessing and expressing 
spaA and possessing at least one other spa-type, was incomplete; only 17% of the 
vaccinated mice survived challenge against this fish strain.  This result suggests that the 
antibodies induced against the SpaA-type swine bacterin were inefficient in inducing an 
effective immune response against the Large Herring 182 challenge, and perhaps the 
spaB/C gene product is antigenically dominant to that of spaA.  
Through the study of spa, it has been found that E. rhusiopathiae and                  
E. tonsillarum differ in their possession of the gene, and to date, no E. tonsillarum strain 
has been found to harbor any gene related to spa [9, 12].  Because E. tonsillarum is non-
pathogenic in swine and most other animals, this obvious genetic difference has led to the 
proposal that Spa proteins may be virulence factors involved in the pathogenesis of        
E. rhusiopathiae [12].  Prior to the vaccination-challenge study, strain lethality testing of 
several E. rhusiopathiae fish and cetacean strains were conducted in nonvaccinated mice.  
One isolate, Large Herring 911, a serotype 21 fish strain possessing at least two spa-types 
and expressing SpaA, did not kill mice.  This result suggests that spaA is not involved 
with virulence; however, the experiment was not designed to investigate the gene’s role 
in causing disease, and this observation is not significant.  The Large Herring 911 strain 
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harbors at least one other spa, and it may be possible that some interaction involving 
these genes may render this particular strain non-pathogenic.  Also, there are many 
factors involved in bacterial virulence, and because this particular E. rhusiopathiae strain 
was isolated from fish, certain virulence mechanisms may not be effective in mice or 
other animal species.  To fully determine the role of spas in pathogenicity, specific 
experiments must be developed which may include the use of a gene knockout mutant. 
In this study, a wide variety of E. rhusiopathiae strains were evaluated for their 
possession and expression of spaA.  It was found that spa-type and serotype are not 
absolutely associated, especially in fish and cetacean strains, and in swine strains other 
than serotypes 1a, 1b, and 2.  Through PCR, it was determined that genetic variation of 
spa may occur within strains or that more spa-types may exist in addition to the three 
currently accepted groups.  A wide range of E. rhusiopathiae strains must be evaluated to 
more fully understand the scope and variability of the spa family of genes.  In addition, 
this study revealed that a single E. rhusiopathiae strain may possess more than one spa-
type which may have effects on immunity and cross-protection.  Further work must be 
done to assess how strains originating from different animal species vary in their 
possession of spa so that more effective bacterins and vaccination protocols can be 
established, especially for marine facilities.   
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 Fujisawa     1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEGKVKGRAPLEAF 1a    
E1-6P        1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEGKVKGRAPLEAF 1a 
SE-9         1 YQSF-------EAVNEEINSIVSELKHEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKGRAPLEAF  2 
Immiayuk     1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKGRAPLEAF  2 
Piquet       1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKGRAPLEAF  ? 
LgH 182      1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKGRAPLEAF  6 
LgH 911      1 YQSF-------EAVNEEINSIVSELKNEGMSLQNIHHMFKQSIQNLATRIGYRSFMQDAMYLENFERLTIPELDEAYVDLLVNYEVKHRILVKYEDKVKGRAPLEAF 21 
Dolphin E1   1 HLDLDSIKNVVESINRQIASLINEIDSEENGPFGIHSTLKQGIHRIAQYIGYNKFMQDAKHLEDFGKLTIPELDEAFVDLLVNYKTSHRTLVKYENKIEDRAPIEAF  6 
715          1 HRDI-------ESINNDINSLIEEIESEENGLYGIHLALKQEIQRIAAELSYYKFTQEAKYLEDSGKLTFPELDEAYIDLLVNHKTSHRTLVKYENKVEGRAPLEAL 18 
 
Fujisawa   101 IVPLRDRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKELHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTI 1a 
E1-6P      101 IVPLRDRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTI 1a 
SE-9       101 IVPLRNRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTI  2 
Immiayuk   101 IVPLRNRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTI  2 
Piquet     101 IVPLRNRIRSMNEIAAEVNYLPEAHEDFLVSDSSEYNDKLSNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYAMRRNRQIQVVRDVYPNLERANAVVESLKTI  ? 
LgH 182    101 IVPLRNRIRSMNEIAVEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYTMRRNRQIQVVRDVYPNLERANAVVESLKTI  6 
LgH 911    101 IVPLRNRIRSMNEIAVEVNYLPEAHEDFLVSDSSEYNDKLNNINFALGLGVSEFIDYNRLENMMEKEIHPLYLELYTMRRNRQIQVVRDVYPNLERANAVVESLKTI 21 
Dolphin E1 108 IVPLINRLKTINELAYEVNRLPEIHEAFLELQSSNLEEKVLEINRVLTPSVAQFIDYSRLEVMMEQEIKPLYLELYLTKQNRQVQLLRDIYPNVDKANKMVEALKGI  6 
715        101 IVPLRSRLRTIHDLSFEVSLLPETHESFLEYQASNIQDKIVEVSRVLAQGVSEFIDYKRLENLMEKEVNPLLLELSTLRRNRQIQMLRDVYPDFEQANELVESLKTT 18 
 
Fujisawa   208 KDIKQRGKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF 1a 
E1-6P      208 KDIKQRGKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF 1a           
SE-9       208 KDIKQREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF  2 
Immiayuk   208 KDIKQREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF  2 
Piquet     208 KDIKQREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF  ? 
LgH 182    208 KDIKQREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF  6 
LgH 911    208 KDIKQREKKLQELLEIYIQRSGDVRKPDVLQRFIGKYQSVVDEEKNKLQDYLESDIFDSYSVDGEKIRNKEITLINRDAYLSMIYRAQSISEIKTIRADLESLVKSF 21 
Dolphin E1 215 EDSEVKSKKVRELLEIYTQRSGDLHSPEVQRRVFGQYYELLQGEKEKLQNYLDSDLFDSHIHTDSKGRNKDIKLINREAFTDMIQNARSMLEIKTIQSDLESILKPK  6 
715        208 QDSKEKYKKFHELLELYIQRGGDIRKQDVFQRFYRTYQTVVEAEKENLRDYLESNIFDSQFVQGEKVKNKEVKLVNRDALLNMIQNARTMVEIKGIQLELDSIAKSF 18 
 
Fujisawa   315 QNEESDSKVEPESPVKVEKPVDEEKPKD 1a 
E1-6P      315 QNEESDSKVEPESPVKVEKPVDEEKPKD 1a 
SE-9       315 QNEESDSKVEPESPVKVEKPVDKEKPKD  2 
Immiayuk   315 QNEESDSKVEPESPVKVEKPVDKEKPKD  2 
Piquet     315 QNEESDSKVEPESPVKVEKPVDKEKPKD  ? 
LgH 182    315 QNEESDSKVEPESPVKVEKPVDKEKPKD  6  
LgH 911    315 QNEESDSKVEPESPVKVEKPVDKEKPKD 21 
Dolphin E1 322 SNEDVDSKVDTE---KVEKPTDQKKPAE  6 
715        315 QKGKGDGKVEPESPIKVEKPGDQKKPGD 18 
 
Figure 3.1 Alignment of the deduced amino acid (AA) sequence of 342 AA of the protective portion of Spa. The sequence starts at AA 90 
of Fujisawa (GenBank accession AB019124) through AA 431 and is aligned with the sequences of E1-6P, SE-9 (AB024084), Immiayuk, 
Piquet, Large Herring 182 (LgH 182), Large Herring 911 (LgH 911), Dolphin E-1 (AB238212) and 715 (AB238210).   Dark highlighted 
sequence indicates identical AA residues among all isolates while light highlighted sequence indicates conserved AA residues.  Dashes 
indicate gaps in the sequence.  Serotype is noted on the right margin.
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IRP529(05) vaccination- challenge results 
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Figure 3.2 Percentage of vaccinated mice surviving challenge with E. rhusiopathiae 
challenge strains E1-6P, Piquet 10507, Immiayuk 6567, Quitz 262, Naluark 10797, 
Kayavak 7122/7155, and Large Herring 182. 
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Table 3.1 Erysipelothrix strains 
Strain Serotype Strain characteristic Source 
185-204  1a  R. L. Wood 
swine isolate collection Fujisawa  1a Japanese challenge strain 
Marienfelde  1a  
Kuniyasu 1a  
ME-7 1a  
E1-6P 1a U. S. challenge strain 
HC-585 1a  
Hydrovac 1a  
DG 1534  1b  
EW-2  1b  
DG 1966 sp 1b  
422-1 1b  
Norden 141  2  
R32E11  2  
FDvac 2  
J80 smooth  2  
10-4   2  
RO-12  2  
R-2 Franklin  2  
T-28  2  
CN 3342  2  
CN 3461 2  
266  2  
Duragen  2  
Yena-36  2  
A1 Japan  2  
AN-4  2  
S-192 2  
ER4 2  
ER5 2  
SE-9  2 U. S. vaccine strain 
ATCC 19414 2  
NF-4 2  
Doggerscharbe 4  
748 4  
Pecs 67 5  
P-190 5  
Castro S66 5  
Castro P23 5  
Castro S52 6  
P32 6  
Tuzok 6  
V1227 8  
Goda 8  
P92 8  
P26 8  
Kaparek 9  
IV 12/8 11  
Pecs 52  11  
Pecs 9 12  
Castro S61 12  
Pecs 3597 15  
Tanzania 16  
545 17  
2017 19  
Baño 36 21  
MEW 22 N   
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Table 3.1 Erysipelothrix strains 
Strain Serotype Relevant characteristic Source 
C2T0 072605 1a  John G. Shedd Aquarium fish 
isolate collection Ariel 100101 1b  
Small herring 032700 2  
C1T1 071204 2  
Capelin 071000 2  
Large Herring 040700 2  
Large Herring 030700 4  
Kri 040201 5  
C2T0 081004 5  
Capelin 032200 5  
Large Herring 071000 6  
Large Herring 073100 6  
Large Herring 182  6  
A  061101 8  
Large Herring 072400 8  
Orange 120301 12  
Small Herring 061200 15  
C2T1 083004  21  
Large Herring 911 21  
Orange 021901 21  
    
Piquet 10507 Xa  John G. Shedd Aquarium Pacific 
white-sided dolphin isolates Quitz 262 [2, 15]b  
    
SW50  8  R. L. Wood collection 
    
Immiayuk 6567 2  John G. Shedd Aquarium Beluga 
whale isolates Kayavak 7122/7155 5  
Naluark 10797 Xa  
    
    
ATCC 43339 7 E. tonsillarum  R. L. Wood collection 
    
a none of the classical serotypes 
b partially identical 
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Table 3.2 PCR and Western blotting results 
Strain Serotype ERY1F/2R Primer 1/2 spaA2F/R Primer 3/4 ERHUB6091 
185-204  1a  Y Y  Y 
Fujisawa  1a Y Y Y  Y 
Marienfelde  1a  Y Y  Y 
Kuniyasu  1a  Y Y  Y 
ME-7  1a  Y Y  Y 
E1-6P 1a Y Y Y O Y 
HC-585 1a  Y Y  Y 
Hydrovac 1a  Y Y  Y 
DG 1534  1b  Y Y  Y 
EW-2  1b  Y Y  Y 
DG 1966 sp 1b  Y Y  Y 
422-1 1b  Y Y  Y 
Norden 141  2  Y Y  Y 
R32E11  2  Y Y  Y 
FDvac 2  Y Y  Y 
J80 smooth  2  Y Y  Y 
10-4  2  Y Y  Y 
RO-12  2  Y Y  Y 
R-2 Franklin  2  Y Y  Y 
T-28  2  Y Y  Y 
CN 3342  2  Y Y  Y 
CN 3461 2  Y Y  Y 
266  2  Y Y  Y 
Duragen  2  Y Y  Y 
Yena-36  2  Y Y  Y 
A1 Japan  2  Y Y  Y 
AN-4  2  Y Y  Y 
S-192 2  Y Y  Y 
ER4 2  Y Y  Y 
ER5 2  Y Y  Y 
SE-9  2 Y Y Y  Y 
ATCC 19414 2  Y Y  Y 
NF-4 2  Y Y  Y 
Doggerscharbe 4 Y O O O O 
748 4 Y O O O O 
Pecs 67 5  Y Y  Y 
P-190 5  Y Y  Y 
Castro S66 5 Y O O O O 
Castro P23 5 Y O O O O 
Castro S52 6 Y O O O O 
P32 6 Y O O O O 
Tuzok 6 Y O O O O 
V1227 8  Y Y  Y 
Goda 8  Y Y  Y 
P92 8 Y O O O O 
P26 8 Y O O O O 
Kaparek 9  Y Y  Y 
IV 12/8 11 Y O O O O 
Pecs 52  11 Y O O O O 
Pecs 9 12  Y Y  Y 
Castro S61 12 Y O O O O 
Pecs 3597 15  Y Y  Y 
Tanzania 16  Y Y  Y 
545 17  Y Y  Y 
2017 19 Y O O O O 
Baño 36 21 Y O O O O 
MEW 22 N  Y Y  Y 
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Table 3.2 PCR and Western blotting results 
Strain Serotype ERY1F/2R Primer 1/2 spaA2F/R Primer 3/4 ERHUB6091 
C2T0 072605 1a Y O O O O 
Ariel 100101 1b  Y Y O Y 
Small Herring 032700 2  Y Y O Y 
C1T1 071204 2  Y Y O Y 
Capelin 071000 2  Y Y O Y 
Large Herring 040700 2  Y Y O Y 
Large Herring 030700 4 Y Y O Y O 
Kri 040201 5 Y O O O O 
C2T0 081004 5 Y O O O O 
Capelin 032200 5  Y Y O Y 
Large Herring 071000 6 Y O O O O 
Large Herring 073100 6 Y O O Y O 
Large Herring 182  6  Y Y Y Y 
A  061101 8 Y O O O O 
Large Herring 072400 8  Y Y O Y 
Orange 120301 12 Y O O O O 
Small Herring 061200 15 Y O O O O 
C2T1 083004  21 Y Y O Y O 
Large Herring 911 21  Y Y Y Y 
Orange 021901 21  Y Y Y Y 
       
Piquet 10507 Xa  Y Y O Y 
Quitz 262 [2, 15]b Y O O O O 
SW50  8 Y O O O O 
Immiayuk 6567 2  Y Y O Y 
Kayavak 7122/7155 5 Y O O O O 
Naluark 10797 Xa Y O O O O 
       
       
ATCC 43339 7 O     
       
a none of the classical serotypes 
b partially identical 
Y positive reaction 
O negative reaction 
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Table 3.3 Mouse challenge strains and dosage  
Strain CFU per challenge LD50 dose Strain origin Serotype 
Piquet 2.5 x 102 7.875 Pacific white-sided dolphin Xa 
Immiayuk 2.7 x 102 7.629 Beluga whale 2 
Quitz 4.0 x 102 7.5 Pacific white-sided dolphin [2, 15]b 
Naluark 3.1 x 102 7.419 Beluga whale Xa 
Kayavak 2.3 x 102 7.629 Beluga whale 5 
Large Herring 182 2.1 x 102 7.567 Herring fish 6 
Large Herring 911 3.76 x 107 c Herring fish 21 
E1-6P 9.12 x 102 8.094 Swine 1a 
a none of the classical serotypes 
b partially identical 
c no pathogenicity in mice, strain not used in vaccination-challenge study 
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CHAPTER 4. GENERAL CONCLUSION 
 
 
Discussion 
In this study, the specificity of monoclonal antibody ERHU-B60-91 was 
determined; several Erysipelothrix rhusiopathiae fish, cetacean, and swine strains were 
evaluated for their possession and expression of spa; and E. rhusiopathiae standard 
reference bacterin IRP 529(05) was examined in its ability to elicit cross-protection in 
mice against fish and cetacean strains of various spa-types.   
A portion of the protective domain of spaA was cloned and expressed and used to 
demonstrate the specificity of the monoclonal antibody, ERHU-B60-91.  The spaA was 
chosen over the other two known spa-types because in this study, it was found that spaA 
is highly conserved in swine strains of serotypes 1a, 1b, and 2, the most common 
serotypes isolated from clinical swine erysipelas.   Previous studies by Imada et al. [1, 2] 
and To and Nagai [3] have shown that the protective domain of spas are responsible for 
eliciting highly protective antibodies against E. rhusiopathiae.  Through Western blotting 
and enzyme-linked immunosorbent assay (ELISA), it was shown that ERHU-B60-91 
specifically recognizes an epitope within the protective domain of SpaA.  ERHU-B60-91 
is used by veterinary biologics manufacturers and the Center for Veterinary Biologics 
(CVB) to measure potency of erysipelas bacterins, and these results validate its use for 
quantifying the protective domain of SpaA in the ELISA potency test.   
Polymerase chain reaction (PCR) assays utilizing spaA, spaB and spaC–specific 
primers were used to survey a wide variety of E. rhusiopathiae swine, fish, and cetacean 
strains.  It was found that spa-type and serotype are not completely associated in these 
strains, except for swine strains of serotypes 1a, 1b, and 2.   Several fish strains of 
serotypes 6 and 21, previously regarded as possessing spaB [3], produced amplicons of 
correct size with spaA-specific primers.  These results were confirmed when the same 
strains also produced a 64-66 kilodalton (kDa) protein recognized by ERHU-B60-91.  A 
PCR assay using published primers to amplify spaB [3] also produced an amplification 
product in several of these same fish strains, which, indicate that a single strain can 
harbor more than one spa. 
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A cross-protection study was conducted in mice to evaluate the cross-
protectiveness of the E. rhusiopathiae standard reference bacterin IRP 529(05) against   
E. rhusiopathiae cetacean and fish strains of various spa-types.  It was found the bacterin 
was highly protective against cetacean strains that harbored a single homologous spaA, 
but was not as efficient against cetacean and fish strains that harbored a heterologous spa 
or strains that possessed more than one spa.  This result implies that efficient protection 
can only be elicited against E. rhusiopathiae challenge strains expressing spas 
homologous to that of the immunizing strain.  It is therefore recommended that the Spa-
type of any E. rhusiopathiae challenge threat should be determined so that a bacterin 
composed of strains expressing homologous Spa-types can be used to elicit complete 
protection. 
 
Recommendations for future research 
 This study has generated several more questions about Spa, and given their 
significance to protection against E. rhusiopathiae infection, it is necessary to continue 
the study of these proteins.  It was found that fish strains varied greatly in the spa-types 
they possessed and that some of these strains possessed more than one spa.  Southern 
hybridization with specific spa probes should be employed to accurately determine the 
combination of spa genes in E. rhusiopathiae and the rate at which this type of genetic 
combination occurs in field isolates.  If this phenomenon is common, differential 
expression studies using microarray technology could be utilized to determine the 
influences of specific spa-type expression.   
A serotype 21 E. rhusiopathiae fish strain possessing spaA and spaB was found 
to be avirulent in mice and raises questions about the gene’s involvement in 
pathogenicity.  The function of the spa family of genes and their expression product is 
not yet known and their possible role in E. rhusiopathiae virulence should be thoroughly 
investigated.  The best method of analysis should be the use of a Spa gene knockout 
mutant. 
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APPENDIX. ADDITIONAL FIGURES 
 
 
Figure A.1  69  
 Electropherogram of amplification products from PCR with primers   
 1 and 2 to amplify whole spaA from E. rhusiopathiae strains. 
 
 
Figure A.2   72 
Electropherogram of amplification products from PCR with primers  
3 and 4 to amplify whole spaB and -C from E. rhusiopathiae strains. 
 
 
Figure A.3   73 
Electropherogram of amplification products from PCR with primers 
spaA2F and spaA2R to amplify the protective domain of spaA from        
E. rhusiopathiae strains. 
 
 
Figure A.4   76 
Electropherogram of amplification products from PCR with primers 
ERY1F and ERY2R to verify species from E. rhusiopathiae strains 
nonreactive with spa-primers. 
 
 
Figure A.5   77 
SDS-PAGE gels of E. rhusiopathiae strains and Western blotting  
with ERHU-B60-91. 
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Figure A.1 
Gel 1 Primer 1/2 
1 A-1 Japan 
2 AN4 
3 S-192 
4 ER4 
5 ER5 
6 SE-9 
7 ATCC 19414 
8 NF4 
9 Doggerscharbe 
10 748 
11 Castro S66 
12 MW 
Gel 2 Primer 1/2 
1 185-204 
2 Fujisawa 
3 Marienfelde 
4 Kuniyasu 
5 ME-7 
6 E1-6P 
7 HC-585 
8 Hydrovac 
9 DG 1534 
10 EW-2 
11 DG 1955 
12 MW 
Gel 3 Primer 1/2 
1 422-1 
2 Norden 141 
3 R32E11 
4 FDvac 
5 J80 smooth 
6 10-4 
7 RO-12 
8 R-2 Franklin 
9 T-28 
10 CN 3342 
11 CN 3461 
12 MW 
   ←12,000 bp 
   ← 2,000 bp 
       
   ← 1,000 bp 
 
 
     1    2      3     4      5     6      7      8     9    10   11    12 
   ←12,000 bp 
   ← 2,000 bp 
       
   ← 1,000 bp 
 
 
  1      2     3     4      5      6     7      8     9    10   11   12 
   ←12,000 bp 
   ← 2,000 bp 
       
   ← 1,000 bp 
 
 
 1     2      3     4      5    6      7     8      9    10    11   12 
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Figure A.1 
Gel 4 Primer 1/2 
1 266 
2 Duragen 
3 Yena-36 
4 Pecs 67 
5 P-190 
6 Castro P23 
7 Castro S52 
8 P32 
9 Tuzok 
10 V1227 
11 Goda 
12 MW 
Gel 5 Primer 1/2 
1 P92 
2 P26 
3 Kaparek 
4 IV 12/8 
5 Pecs 52 
6 Pecs 9 
7 Castro S61 
8 Pecs 3597 
9 Tanzania 
10 545 
11 2017 
12 MW 
Gel 6 Primer 1/2 
1 Baño 36 
2 MEW 22 
3 C2T0 072605 
4 Ariel 101201 
5 Small herring 032700 
6 C1T1 071204 
7 Capelin 071000 
8 Large herring 040700 
9 Large herring 030700 
10 Kri 040201 
11 C2T0 081000 
12 MW 
Gel 4 
    ←12,000 bp 
    ← 2,000 bp 
       
    ← 1,000 bp 
 
 
  1      2     3      4     5     6      7      8       9   10   11    12 
    ←12,000 bp 
    ← 2,000 bp 
       
    ← 1,000 bp 
 
 
   1     2      3     4     5      6      7      8      9    10   11    12 
    ←12,000 bp 
    ← 2,000 bp 
       
    ← 1,000 bp 
 
 
      
   1      2     3      4     5      6     7      8     9    10   11     12 
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Figure A.1
Gel 7 Primer 1/2 
1 Capelin 032200 
2 Large herring 071000 
3 Large herring 073100 
4 Large herring 182 
5 A 061101 
6 Large herring 072400 
7 Orange 120301 
8 Large herring 061200 
9 C2T1 083004 
10 Large herring 911 
11 Orange 031901 
12 MW 
Gel 8 Primer 1/2 
1 Piquet 10507 
2 Quitz 262 
3 SW50 
4 Immiayuk 6567 
5 Kayavak 7122/7155 
6 Naluark 
7 MW 
8 Empty 
9 Empty 
10 Empty 
11 Empty 
12 Empty 
  ←12,000 bp 
  ← 2,000 bp 
       
  ← 1,000 bp 
 
 
 1      2     3      4     5      6      7     8      9    10   11    12 
    1     2     3      4       5     6      7      8     9    10   11    12 
      ←12,000 bp 
      ← 2,000 bp 
       
      ← 1,000 bp 
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Figure A.2
Gel 1 Primer 3/4 
1 E1-6P 
2 C2T0 072605 
3 Large herring 030700 
4 Kri 040201 
5 C2T0 081004 
6 Large herring 071000 
7 A 061101 
8 Orange 120301 
9 Small herring 061200 
10 C2T1 083004 
11 Large herring 073100 
12 MW 
Gel 2 Primer 3/4 
1 Large herring 182 
2 Large herring 911 
3 Orange 021901 
4 Doggerscharbe 
5 Tuzok 
6 IV 12/8 
7 2017 
8 Baño 36 
9 748 
10 Castro S66 
11 Castro P23 
12 MW 
Gel 3 Primer 3/4 
1 Large herring 073100 
2 Castro S52 
3 P32 
4 P92 
5 P26 
6 Pecs 52 
7 Castro S61 
8 Doggerscharbe 
9 IV 12/8 
10 Baño 36 
11 C2T1 083004 
12 MW 
  1     2     3     4      5      6     7      8      9    10    11   12 
←12,000 bp 
← 2,000 bp 
       
← 1,000 bp 
 
 
 1      2     3     4      5      6     7      8     9    10    11   12 
←12,000 bp 
← 2,000 bp 
       
← 1,000 bp 
 
 
       1    2     3     4      5      6     7     8      9     10    11   12 
   ←12,000 bp 
   ← 2,000 bp 
       
   ← 1,000 bp 
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Figure A.3 
Gel 1 Primer spaA2 
1 Yena 36 
2 A1 Japan 
3 AN-4 
4 S-192 
5 ER4 
6 ER5 
7 SE-9 
8 ATCC 19414 
9 NF-4 
10 Doggerscharbe 
11 748 
12 MW 
Gel 2 Primer spaA2 
1 Pecs 67 
2 P-190 
3 Castro S66 
4 Castro P23 
5 Castro S52 
6 P32 
7 Tuzok 
8 V1227 
9 Goda 
10 P92 
11 P26 
12 MW 
Gel 3 Primer spaA2 
1 Kaparek 
2 IV 12/8 
3 Pecs 52 
4 Pecs 9 
5 Castro S61 
6 Pecs 3597 
7 Tanzania 
8 545 
9 2017 
10 Baño 36 
11 MEW 22 
12 MW 
1      2      3     4      5     6     7      8      9   10    11   12 
   
  ←12,000 bp 
  ← 2,000 bp 
       
  ← 1,000 bp 
 
 
        1      2     3     4      5      6     7      8     9    10    11   12 
   
  ←12,000 bp 
  ← 2,000 bp 
        
  ← 1,000 bp 
 
 
    1      2      3      4     5     6     7      8      9    10    11   12 
   
  ←12,000 bp 
  ← 2,000 bp 
       
  ← 1,000 bp 
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Figure A.3
Gel 4 Primer spaA2 
1 185-204 
2 Fujisawa 
3 Marienfelde 
4 Kuniyasu 
5 ME-7 
6 E1-6P 
7 HC-585 
8 Hydrovac 
9 DG 1534 
10 EW-2 
11 DG 1966 sp 
12 MW 
Gel 5 Primer spaA2 
1 422-1 
2 Norden 141 
3 R32E11 
4 FDvac 
5 J80 smooth 
6 10-4 
7 RO-12 
8 R-2 Franklin 
9 T-28 
10 CN 3342 
11 CN 3461 
12 MW 
Gel 6 Primer spaA2 
1 266 
2 Duragen 
3 C2T0 072605 
4 Ariel 100101 
5 Small herring 032700 
6 C1T1 071204 
7 Capelin 071000 
8 Large herring 040700 
9 Large herring 030700 
10 Kri 040201 
11 C2T0 081004 
12 MW 
        1      2      3      4      5      6      7     8       9     10   11    12 
   
 ←12,000 bp 
 ← 2,000 bp 
       
 ← 1,000 bp 
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Figure A.3
Gel 7 Primer spaA2 
1 Large herring 071000 
2 Large herring 073100 
3 Capelin 032200 
4 Large herring 182 
5 A 061101 
6 Large herring 072400 
7 Orange 120301 
8 Small herring 061200 
9 C2T1 083004 
10 Large herring 911 
11 Orange 021901 
12 MW 
Gel 8 Primer spaA2 
1 Doggerscharbe 
2 Piquet 01507 
3 Quitz 262 
4 SW50 
5 Immiayuk 6567 
6 Kayavak 7122/7155 
7 Naluark 10797 
8 Kaparek 
9 422-1 
10 266 
11 185-204 
12 MW 
    1      2      3     4      5      6      7      8      9    10    11    12 
   
 ←12,000 bp 
 ← 2,000 bp 
       
 ← 1,000 bp 
 
 
    1     2      3     4       5     6      7       8      9    10     11   12 
   
 ←12,000 bp 
 ← 2,000 bp 
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Figure A.4
Gel 1 Primer ERY1F/2R 
1 E1-6P 
2 Doggersharbe 
3 748 
4 Castro S66 
5 Castro P23 
6 Castro S52 
7 P32 
8 Tuzok 
9 P92 
10 P26 
11 ATCC 43339 
12 MW 
Gel 2 Primer ERY1F/2R 
1 IV 12/8 
2 Pecs 52 
3 Castro S61 
4 2017 
5 Baño 36 
6 C2T0 072605 
7 Large herring 030700 
8 Kri 040201 
9 C2T0 081004 
10 Large herring 071000 
11 ATCC 43339 
12 MW 
Gel 3 Primer ERY1F/2R 
1 SE-9 
2 Large herring 073100 
3 A 061101 
4 Orange 120301 
5 Small herring 061200 
6 C2T1 083004 
7 Quitz 262 
8 SW50 
9 Kayavak 7122/7155 
10 Naluark 10797 
11 Fujisawa 
12 MW 
          ←12,000 bp 
          ← 2,000 bp 
         
          ← 1,000 bp 
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Figure A.5 
Blot #1  
1 MW 
2 185-204 
3 Doggerscharbe 
4 FDvac 
5 Marienfelde 
6 Kuniyasu 
7 ME-7 
8 EW-2 
9 DG 1966 
10 DG 1534 
11 Norden 141 
12 Orange 021901 
Blot #2  
1 J80 smooth 
2 MW 
3 IV 12/8 
4 RO-12 
5 R-2 Franklin 
6 T-28 
7 Baño 36 
8 Duragen 
9 ER4 
10 ER5 
11 Yena-36 
12 C2T0 072605 
Blot #3 
1 HC-585 
2 Doggerscharbe 
3 MW 
4 S-192 
5 Orange 120301 
6 Small herring 061200 
7 Pecs 67 
8 P-190 
9 Goda 
10 Kaparek 
11 Pecs 9 
12 Tuzok 
    1    2    3    4    5    6    7    8    9   10  11  12 
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Figure A.5 
Blot #4 
1 Tanzania 
2 545 
3 MEW 22 
4 MW 
5 Ariel 100101 
6 Small herring 032700 
7 C1T1 071204 
8 Capelin 071000 
9 Large herring 040700 
10 Capelin 032200 
11 C2T0 072605 
12 SE-9  
Blot #5 
1 Empty 
2 MW  
3 10-4 
4 266 
5 A1 Japan 
6 422-1 
7 Large herring 072400 
8 R32E11 
9 NF-4 
10 Hydrovac 
11 Pecs 3597 
12 ATCC 19414 
Blot #6  
1 748 
2 Castro S52 
3 P32 
4 Tuzok 
5 Pecs 52 
6 Castro S66 
7 LgH 7/31/00 
8 SE-9 
9 MW 
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Figure A.5 
Blot #7  
1 MW 
2 SE-9 
3 Castro P23 
4 P92 
5 P26 
6 Castro S61 
7 Kri 4/02/01 
8 C2T0 8/10/04 
9 A 6/11/01 
Blot #8  
1 V1227 
2 LgH 4 3/7/00 
3 LgH 911 
4 LgH 182 
5 C2T1 8/30/04 
6 Orange 21 
7 LgH  7/10/00 
8 Doggersharbe 
9 IV 12/8 
10 2017 
11 Baño 36 
12 MW 
Total protein blot #9  
1 Piquet broth supernatant 
2 Piquet wash 1 supernatant 
3 Piquet membrane extract 
4 Quitz broth supernatant 
5 Quitz wash 1 supernatant 
6 Quitz membrane extract 
7 Immiayuk broth supernatant 
8 Immiayuk wash 1 supernatant 
9 Immiayuk membrane extract 
10 MW 
11 Uninoculated broth control 
12 Empty (lane cut off) 
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Figure A.5 
Western blot #9 
1 Piquet broth supernatant 
2 Piquet wash 1 supernatant 
3 Piquet membrane extract 
4 Quitz broth supernatant 
5 Quitz wash 1 supernatant 
6 Quitz membrane extract 
7 Immiayuk broth supernatant 
8 Immiayuk wash 1 supernatant 
9 Immiayuk membrane extract 
10 MW 
11 Empty (lane cut off ) 
12 Empty (lane cut off) 
Total protein blot #10  
1 Naulark broth supernatant 
2 Naluark wash 1 supernatant 
3 Naluark membrane extract 
4 Kayavak broth supernatant 
5 Kayavak wash 1 supernatant 
6 Kayavak membrane extract 
7 Kayvak broth supernatant 
8 Kayavak wash 1 supernatant 
9 Kayavak membrane extract 
10 MW 
11 Negative broth control 
12 Empty (lane cut off) 
Western blot #10  
1 Naulark broth supernatant 
2 Naluark wash 1 supernatant 
3 Naluark membrane extract 
4 Kayavak broth supernatant 
5 Kayavak wash 1 supernatant 
6 Kayavak membrane extract 
7 Kayvak broth supernatant 
8 Kayavak wash 1 supernatant 
9 Kayavak membrane extract 
10 MW 
11 Negative broth control 
12 MW 
         1      2        3      4      5      6       7     8       9    10  
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Figure A.5 
Total protein blot #11  
1 MW 
2 SE-9 membrane extract 
3 Piquet membrane extract 
4 Immiayuk membrane extract 
Western blot #11  
1 MW 
2 SE-9 membrane extract 
3 Piquet membrane extract 
4 Immiayuk membrane extract 
Blot #12  
1 MW 
2 AN-4 broth supernatant 
3 AN-4 wash 1 supernatant 
4 AN-4 membrane extract 
5 MW 
6 Empty 
7 Empty 
8 CN 3342 broth supernatant 
9 CN 3342 wash 1 supernatant 
10 CN 3342 membrane extract 
11 MW 
12 empty 
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Figure A.5 
Gel #12  
1 MW 
2 AN-4 broth supernatant 
3 AN-4 wash 1 supernatant 
4 AN-4 membrane extract 
5 MW 
6 Empty 
7 Empty 
8 CN 3342 broth supernatant 
9 CN 3342 wash 1 supernatant 
10 CN 3342 membrane extract 
11 MW 
12 empty 
Blot #13  
1 MW 
2 Empty 
3 SE-9 membrane extract 
4 SE-9 wash 2 supernatant 
5 SE-9 wash 1 supernatant 
6 SE-9 broth supernatant 
7 MW 
8 E1-6P membrane extract 
9 E1-6P wash 2 supernatant 
10 E1-6P wash 1 supernatant 
11 E1-6P broth supernatant 
12 Empty 
Gel #13  
1 MW 
2 Empty 
3 SE-9 membrane extract 
4 SE-9 wash 2 supernatant 
5 SE-9 wash 1 supernatant 
6 SE-9 broth supernatant 
7 MW 
8 E1-6P membrane extract 
9 E1-6P wash 2 supernatant 
10 E1-6P wash 1 supernatant 
11 E1-6P broth supernatant 
12 Empty 
 1    2     3    4    5     6    7     8    9   10   11  12  
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Figure A.5 
Blot #14  
1 Empty 
2 CN 3461 broth supernatant 
3 CN 3461 wash 1 supernatant 
4 CN 3461 membrane extract 
5 MW 
6 Empty 
7 Empty 
8  MW 
9 Fujisawa broth supernatant 
10 Fujisawa wash 1 supernatant 
11 Fujisawa membrane extract 
12 Empty 
Gel #14 
1 Empty 
2 CN 3461 broth supernatant 
3 CN 3461 wash 1 supernatant 
4 CN 3461 membrane extract 
5 MW 
6 Empty 
7 Empty 
8  MW 
9 Fujisawa broth supernatant 
10 Fujisawa wash 1 supernatant 
11 Fujisawa membrane extract 
12 Empty 
   1      2     3     4    5    6     7     8     9   10   11   12 
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